Researcher basic information

• 博士（生命科学）, 北海道大学

• https://researchmap.jp/yukis?lang=en

• https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201301019597444455
• http://kaken.nii.ac.jp/d/r/00564981.ja.html

• 201301019597444455

• hyaluronan
• carotenoid
• Oxidative stress
• 小腸
• 吸収
• 腎臓
• pharmaceutics
• emulsion
• 抗酸化
• トランスポーター
• 機能性食品
• がん

• Life Science, Clinical pharmacy

• Bachelor's degree program, School of Pharmaceutical Sciences and Pharmacy
• Master's degree program, Graduate School of Life Science
• Doctoral (PhD) degree program, Graduate School of Life Science

Research activity information

• May 2017, 日本薬学会北海道支部, Young investigator award
  Study of formulation development based on the pharmacokinetic properties of functional food components
  Yuki Sato
• 2014, 日本コエンザイムＱ協会, 奨励賞
  Coenzyme Q10の消化管吸収改善
  佐藤夕紀
• Sep. 2013, 日本医療薬学会, Postdoctoral Award
  機能性食品成分の体内動態特性を考慮した製剤開発に関する研究
  Yuki Sato
• May 2009, 日本薬剤学会, 日本薬剤学会永井財団大学院学生スカラシップ
  佐藤夕紀
• 2007, 日本医療薬学会, 第17回日本医療薬学会年会 優秀発表賞
  ルテインの吸収動態の解明と酸化障害抑制効果に対する検討
  佐藤夕紀

• Development of a method of liquid chromatography coupled with tandem mass spectrometry for simultaneous determination of hyaluronan oligosaccharide in plasma.
  Nao Takabayashi; Yuki Sato; Kuma Aoyagi; Shunsuke Nashimoto; Hitoshi Kashiwagi; Yoh Takekuma; Mitsuru Sugawara
  Food research international (Ottawa, Ont.), 236, 119273, 119273, 31 Jul. 2026, [Peer-reviewed], [Corresponding author], [International Magazine]
  English, Scientific journal, Hyaluronan (HA) exists in the body with various molecular weights ranging from several hundred to several million. Recently the physiological functions of HA oligosaccharides, in addition to high-molecular weight HA, have been reported. It is important to clarify the relationship between physiological function and pharmacokinetics. When HA is ingested orally, most of it is broken down into HA oligosaccharides less than 8-mers by the gut microbiota and absorbed. However, there is no method to simultaneously determine these HA oligosaccharides. This study aimed to elucidate the pharmacokinetics of exogenous HA, in plasma samples, by developing a simple pretreatment and highly sensitive simultaneous determination method for HA less than 8-mers. First, carboxy groups of HA oligosaccharides were derivatized with a condensing reagent (DMT-MM) and Girard's reagent P. After pretreatment by solid-phase extraction using hydrophilic interaction, peaks of HA 2, 4, 6 and 8-mer were detected by LC-MS/MS. Validation studies were conducted for this method. Additionally, plasma concentrations of HA were determined after oral administration of HA formulation to rats. We confirmed by MS scan that the derivatized HA oligosaccharides could be analyzed by the developed quantitative method and identified the peak of derivatized HA oligosaccharides. The MS/MS conditions were optimized, and a calibration curve was generated, which showed good linearity for HA 4, 6, and 8-mer. This method was valid and enabled measurement of HA 4, 6, and 8-mer concentrations in plasma. This simultaneous analytical method can reduce experiment time compared to conventional methods.
• Risk factors of docetaxel-induced peripheral edema in non-small cell lung cancer treatment: a multi-institutional cohort study.
  Shinsuke Yamashita; Yoshitaka Saito; Shinya Tamaki; Daisuke Hirate; Karin Wakai; Itsuki Yonezawa; Honoka Hirasawa; Hitoshi Kashiwagi; Yuki Sato; Shungo Imai; Shunsuke Nashimoto; Jun Sakakibara-Konishi; Yasushi Shimizu; Ichiro Kinoshita; Ryo Takagi; Mitsuru Sugawara; Yoh Takekuma
  Japanese journal of clinical oncology, 26 Jul. 2026, [Peer-reviewed], [International Magazine]
  English, Scientific journal, BACKGROUND: Peripheral edema is an adverse event associated with docetaxel (DTX). However, previous studies on DTX-induced peripheral edema have been limited to patients with breast cancer. Therefore, evaluation of symptoms in other cancer types is essential. We aimed to identify the factors associated with this symptom in patients with non-small cell lung cancer (NSCLC). METHODS: This retrospective multicenter observational study evaluated 170 patients with NSCLC who received DTX between April 2014 and December 2024. The primary endpoint was factors associated with grade ≥ 2 DTX-induced peripheral edema during up to seven cycles. Additionally, we evaluated the factors for all-grade symptoms. RESULTS: The incidences of grade ≥ 2 and all-grade DTX-induced peripheral edema were 13.5% and 30.0%. The median cumulative DTX dose at symptom onset was 144 (interquartile range, 60-254) mg/m2 for grade ≥ 2 DTX-induced peripheral edema and 120 (60-210) mg/m2 for all-grade symptoms. The Fine-Gray sub-distribution hazard models revealed that the co-administration of ramucirumab (RAM) was significantly associated with the incidence of DTX-induced peripheral edema (grade ≥ 2: sub-distribution hazard ratio [SDHR], 3.51; 95% confidence interval [CI], 1.34-9.24; P = 0.011) (all-grade: SDHR, 2.17; 95% CI, 1.20-3.92; P = 0.011). The Gray's test demonstrated that the cumulative incidence of DTX-induced peripheral edema was significantly higher in the DTX + RAM group than in the DTX monotherapy group (P = 0.003 and < 0.001 for grade ≥ 2 and all-grade symptoms, respectively). CONCLUSIONS: We revealed that co-administration of RAM is a risk factor for DTX-induced peripheral edema in patients with NSCLC.
• Hyperfiltration in Critically Ill Older Adults: Incidence, Risk Factors, Time Course, and Predictive Performance of Kidney Function Estimation
  Ryusei Mikami; Shungo Imai; Mineji Hayakawa; Gaku Izumi; Hitoshi Kashiwagi; Yuki Sato; Shunsuke Nashimoto; Takeshi Wada; Mitsuru Sugawara; Yoh Takekuma
  Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 46, 6, e70153, Jun. 2026, [Peer-reviewed], [International Magazine]
  English, Scientific journal, STUDY OBJECTIVE: This study aimed to evaluate the incidence, associated risk factors, time course, and predictive performance of kidney function estimation equations for hyperfiltration in critically ill older adults. METHODS: This retrospective observational study evaluated 325 patients (median age, 76 years) admitted to the intensive care unit (ICU) of a tertiary-care university hospital, for a total of 2934 patient-days. The hyperfiltration threshold was defined using measured creatinine clearance (Clcr) > -0.883 × age + 167.398. Independent factors associated with hyperfiltration were identified via a multivariable logistic regression model, and time to onset and duration were evaluated using Kaplan-Meier curves. Additionally, the predictive performance of the measured Clcr was assessed using the Cockcroft-Gault equation. Bias was analyzed using the Bland-Altman analysis, and accuracy was evaluated using the percentage within 30% of the measured Clcr (P30). RESULTS: Hyperfiltration occurred in 56% of the patients. Risk factors included male sex, high body mass index, trauma-related admission, vasopressor use, and low serum creatinine levels. The median time from ICU admission to hyperfiltration onset was 5 days, and the median duration of hyperfiltration episodes was 8 days. The Cockcroft-Gault equation substantially underestimated measured Clcr in patients with hyperfiltration. Even among those whose measured Clcr did not meet the conventional augmented renal clearance (ARC) threshold (> 130 mL/min), the equation exhibited a clinically significant negative bias (-35 mL/min) with limited accuracy (P30: 39%). This underestimation was even more pronounced in patients meeting the ARC criteria (bias: -62 mL/min; P30: 27%). CONCLUSIONS: Hyperfiltration is highly prevalent in critically ill older adults. The Cockcroft-Gault equation substantially underestimated actual kidney function, even without meeting the ARC criteria. Continuous monitoring of the measured Clcr is recommended to avoid inappropriate medication dose reductions due to underestimation.
• Linezolid-Induced Serotonin Release from QGP-1 Cells.
  Takezo Tsutsumi; Hitoshi Kashiwagi; Shungo Imai; Yuki Sato; Shunsuke Nashimoto; Mitsuru Sugawara; Yoh Takekuma
  Drug research, 76, 4-06, 125, 130, 02 Mar. 2026, [Peer-reviewed], [International Magazine]
  English, Scientific journal, Nausea and vomiting are commonly reported side effects of long-term linezolid therapy, which is indispensable for tuberculosis and osteoarticular infections. Since the mechanism underlying the development of nausea and vomiting during linezolid treatment is unknown, this study aimed to explore the mechanisms by focusing on the monoamine oxidase-inhibiting effect of linezolid.In vitro serotonin release assays were performed using QGP-1 cells as a surrogate for enterochromaffin cells exposed to linezolid, the monoamine oxidase inhibitor clorgyline, and the known emetogenic agent cisplatin. Serotonin concentrations in the solutions were measured using an enzyme-linked immunosorbent assay. Clorgyline and cisplatin were administered simultaneously with linezolid to elucidate the serotonin release mechanism and confirm the synergistic effects. The intracellular Ca2+assays using Fura‑2 were also performed to assess whether serotonin release is mediated by Ca2+‑dependent exocytosis.Linezolid exposure significantly increased serotonin release from QGP-1 cells in concentration- and time-dependent manners. Serotonin release also increased in the clorgyline exposure group, and the release of serotonin in the linezolid/clorgyline co-exposure group was higher than that in the single-exposure groups. In contrast, no significant serotonin release or synergistic effects were observed in the cisplatin/linezolid-exposed groups. The Ca2+assays demonstrated that linezolid exposure did not change intracellular Ca2+levels.Serotonin release was observed when QGP-1 cells were exposed to linezolid, an effect similar to that observed with the potent monoamine oxidase A inhibitor clorgyline. Furthermore, the Ca2+assays indicated that linezolid‑induced serotonin release occurs independently of Ca2+‑dependent exocytosis.
• 薬剤師のための消化管の知識(No.9) 小腸における薬物吸収 トランスポーターや代謝酵素に着目した新たな評価系
  佐藤 夕紀
  Helicobacter Research, 29, 2, 191, 195, (株)先端医学社, Dec. 2025
  Japanese
• Temporal effects of empirical round-up of serum creatinine on the accuracy of estimated kidney function after critical illness.
  R Mikami; S Imai; M Hayakawa; H Kashiwagi; Y Sato; S Nashimoto; M Sugawara; Y Takekuma
  Die Pharmazie, 80, 9, 93, 101, 01 Oct. 2025, [Peer-reviewed], [International Magazine]
  English, Scientific journal, This study aimed to evaluate the temporal effect of a serum creatinine (SCr) correction intervention in critically ill patients with daily muscle wasting. A total of 5,355 critical care days in 574 patients with creatinine clearance (Clcr) and glomerular filtration rate (GFR) measured and estimated simultaneously were included. The primary endpoint was the difference in accuracy over time of the estimated Clcr/GFR relative to the measured Clcr. The CG equation was used to estimate Clcr, and the MDRD and CKD-EPI-equations were used to estimate GFR. Estimated Clcr(round-up)/GFR(round-up) indicates the estimated Clcr/GFR calculated using the rounded up value if SCr was <0.6 mg/dL. Bias was analyzed using Bland-Altman analysis, correlation using Spearman's rank correlation coefficient, and accuracy using percentage within 30% of the measured Clcr (P30). The CKD-EPI equation showed a large underestimation bias in the early period, whereas the CG and MDRD equations indicated large overestimation biases in the later period. Round-up correction increased the underestimation bias in the early period of the CG(round-up) and MDRD(round-up) equations, but decreased the overestimation bias in the later period. The limits of agreements for the CG(round-up) and MDRD(round-up) equations were narrower, although not consistently acceptable. The correlations were stronger for the CG(round-up) and MDRD(round-up) equations. Accuracy did not improve with the corrective intervention. Conclusion: SCr round-up correction increased the underestimation of kidney function in the early phase, but mitigated overestimation in the later phase. The limits of agreement remained unacceptable, and the accuracy did not improve.
• Temporal effects of errors in estimating kidney function after critical illness on drug dosing categories
  Ryusei Mikami; Shungo Imai; Mineji Hayakawa; Kento Sabashi; Hitoshi Kashiwagi; Yuki Sato; Shunsuke Nashimoto; Mitsuru Sugawara; Yoh Takekuma
  British Journal of Clinical Pharmacology, 92, 1, 162, 171, Wiley, 26 Aug. 2025, [Peer-reviewed], [International Magazine]
  English, Scientific journal, Aims
  
  This study aimed to clarify how the trajectories of the Cockcroft–Gault (CG), Modification of Diet in Renal Disease (MDRD) and Chronic Kidney Disease Epidemiology Collaboration (CKD‐EPI) equations differ from measured creatinine clearance (Clcr) and to determine their impact on drug dosing categories in critically ill patients.
  
  Methods
  
  We used data from 5355 days following critical illness to estimate the trajectories of the above‐mentioned kidney function equations using a linear mixed model. In addition, we determined whether the CG, MDRD and CKD‐EPI equations would change drug dosing categories (<15, 15–29, 30–59, 60–89, 90–119, 120–149, or ≥150 mL/min) over time compared with that observed using measured Clcr.
  
  Results
  
  The rate of change relative to baseline in measured Clcr remained almost unchanged during the 28 days of observation (−0.02 [95% confidence interval, CI: −0.19–0.14] mL/min/1.73 m²/day). In contrast, all indirect kidney function estimating equations showed a time‐dependent increase in the rate of change, which was largest for the CG equation, followed by the MDRD and CKD‐EPI equations (+2.00 [95% CI: 1.89–2.12], +1.50 [95% CI: 1.34–1.67] and +0.77 [95% CI: 0.61–0.93] mL/min/1.73 m²/day, respectively). More than half of the CG, MDRD and CKD‐EPI equations showed discrepancies with the measured Clcr and drug dosing categories, with underestimation in the early phases and overestimation in the later phases being more common.
  
  Conclusion
  
  Creatinine‐based indirect kidney function estimation equations increased over time, indicating erroneous drug dosing categories on over half of the critical care days.
• Evaluation of Transport Activity Using Mouse Jejunal Epithelial Cell Monolayer Culture System.
  Yoshiki Sasagawa; Riho Kamishima; Hitoshi Kashiwagi; Yuki Sato; Shunsuke Nashimoto; Yoh Takekuma; Mitsuru Sugawara
  Biological & pharmaceutical bulletin, 48, 8, 1199, 1206, 2025, [Peer-reviewed], [Domestic magazines]
  English, Scientific journal, Caco-2 cells, derived from colorectal cancer cells, are generally used to evaluate drug absorption in the gastrointestinal tract. However, differences between Caco-2 and normal intestinal cells have been observed. Cells cultured directly from crypts are maintained in their biological state. Therefore, we developed a rapid and easy method of monolayer culture of epithelial cells isolated from the jejunum of mice. We analyzed the usefulness of the jejunal epithelial cell monolayer culture system as a research tool and evaluated changes in the transport activity and mRNA expression of transporters. We focused on P-glycoprotein (P-gp) and peptide transporter 1 (Pept1) as representative transporters expressed in the small intestine. A P-gp inhibitor significantly enhanced the accumulation of Rhodamine 123 (Rho123), a substrate of P-gp, indicating that the transport activity of P-gp could be evaluated. Uptake of glycylsarcosine, a Pept1 substrate, significantly decreased in the presence of the Pept1 inhibitor, indicating that the transport activity of Pept1 could be evaluated. Rho123 accumulation significantly decreased in the group treated with calcitriol, an inducer of P-gp and Cyp3a11, suggesting that changes in P-gp expression could be evaluated. Furthermore, we examined whether mRNA expression levels of transporters and drug-metabolizing enzyme were altered. In the calcitriol-supplemented group, P-gp and Cyp3a11 mRNA levels significantly increased. However, no significant differences were observed in Pept1 mRNA levels. Overall, the jejunal epithelial cell monolayer culture system developed from intestinal tissues is a useful research tool for assessing the transport activities and expression variabilities of transporters.
• Actual Use of Budesonide Enteric-Coated Capsules for Crohn's Disease in Japan: Analysis of Health Insurance Big Data.
  Keiji Yagisawa; Atsuhito Kubota; Shungo Imai; Shunsuke Nashimoto; Yuki Sato; Hitoshi Kashiwagi; Atsuo Maemoto; Mitsuru Sugawara; Yoh Takekuma
  Biological & pharmaceutical bulletin, 48, 1, 33, 38, 2025, [Peer-reviewed], [Domestic magazines]
  English, Scientific journal, Using a large health insurance database in Japan, we examined the real-world usage of budesonide enteric-coated capsules (BUD) in treating Crohn's disease. We analyzed data from the Japan Medical Data Center claims database for Crohn's disease patients prescribed BUD from April 2016 to March 2021, focusing on prescription status, adverse events (AEs), monitoring tests, and concomitant medications over 2 years following BUD initiation. Patients were categorized into two groups based on BUD usage duration: ≤1 year and >1 year. Of the 7364 registered patients, 1049 (14.2%) were prescribed BUD. Among the 562 followed for 2 years, 505 (89.9%) used BUD for ≤1 year and 57 (10.1%) for >1 year. Over 70% of the patients used at least one biologic, and more than 20% used at least two. The proportions of new thiopurine initiation were 22 and 9% in the ≤1-year and >1-year groups, respectively (p = 0.0181). We did not identify any obvious increase in AEs from long-term BUD use within the confines of our study design. However, regardless of prescription duration, over half of the patients lacked hepatitis B virus screening, glycated hemoglobin measurement, adrenal function quantification, or bone densitometry. Usage of strong CYP3A4 inhibitors was more frequent among patients in the BUD >1-year group. This study revealed that numerous Japanese patients received long-term BUD prescriptions. Although no apparent increase in AEs from long-term BUD was detected, we identified inadequate monitoring of AEs and drug interactions, as well as insufficient use of steroid-sparing agents.
• Impact of Eye Contact on Communication during Online Medication Counseling: An Analysis Using the Roter Interaction Analysis System.
  Ayako Mori; Izumi Kato; Katsuya Narumi; Yoh Takekuma; Shuhei Ishikawa; Hitoshi Kashiwagi; Yuki Sato; Mitsuru Sugawara; Masaki Kobayashi
  Biological & pharmaceutical bulletin, 48, 1, 17, 22, 2025, [Peer-reviewed], [Domestic magazines]
  English, Scientific journal, We have previously used the Roter Interaction Analysis System (RIAS) to analyze differences between online and face-to-face medication counseling. In our previous research, students have commented that the built-in camera on their laptops makes it difficult to make eye contact and communicate effectively. Furthermore, there is a lack of research on the impact of eye contact in online medical communication. Therefore, this study aimed to investigate the effects of eye contact on online medication counseling. Two simulated patients (SPs) and 10 pharmacy students acting as pharmacists were enrolled in this clinical study (ID:2022-001). Participants were divided into 2 groups: one using cameras designed to naturally align eye contact and another using standard device cameras. The dialogues were segmented into meaningful minimal units (utterances), categorized using RIAS according to their nature, and analyzed. Scenarios with aligned eye contact significantly increased the total number of SP utterances and the occurrence and proportion of "Check" utterances by students, confirming their understanding. The increase in the total utterance count of SPs was associated with a corresponding increase in the number of "Agree" utterances indicating agreement and understanding. Thus, eye contact enhances the clarity of patient responses and proactively confirms patient understanding, thereby mitigating the difficulty of assessing comprehension and conducting bidirectional communication online. This study's findings quantitatively suggested that eye contact in online medication counseling enhances proactive engagement in communication for pharmacy students and SPs.
• Development and validation of the prediction score for augmented renal clearance in critically Ill Japanese adults.
  Ryusei Mikami; Shungo Imai; Mineji Hayakawa; Hitoshi Kashiwagi; Yuki Sato; Shunsuke Nashimoto; Mitsuru Sugawara; Yoh Takekuma
  Journal of pharmaceutical health care and sciences, 10, 1, 69, 69, 06 Nov. 2024, [Peer-reviewed], [International Magazine]
  English, Scientific journal, BACKGROUND: Augmented renal clearance (ARC) decreases the therapeutic concentration of drugs excreted by the kidneys in critically ill patients. Several ARC prediction models have been developed and validated; however, their usefulness in Japan has not been comprehensively investigated. Thus, we developed a unique ARC prediction model for a Japanese mixed intensive care unit (ICU) population and compared it with existing models. METHODS: This retrospective study enrolled a mixed ICU population in Japan from January 2019 and June 2022. The primary outcome was the development and validation of a model to predict ARC onset based on baseline information at ICU admission. Patients admitted until May 2021 were included in the training set, and external validation was performed on patients admitted thereafter. A multivariate logistic regression model was used to develop an integer-based predictive scoring system for ARC. The new model (the JPNARC score) was externally validated along with the ARC and Augmented Renal Clearance in Trauma Intensive Care (ARCTIC) scores. RESULTS: A total of 2,592 critically ill patients were enrolled initially, with 651 patients finally included after excluding 1,941 patients. The training and validation datasets comprised 456 and 195 patients, respectively. Multivariate analysis was performed to develop the JPNARC score, which incorporated age, sex, serum creatinine, and diagnosis upon ICU admission (trauma or central nervous system disease). The JPNARC score had a larger area under the receiver operating characteristic curve than the ARC and ARCTIC scores in the validation dataset (0.832, 0.633, and 0.740, respectively). CONCLUSIONS: An integer-based scoring system was developed to predict ARC onset in a critically ill Japanese population and showed high predictive performance. New models designed to predict the often-unrecognized ARC phenomenon may aid in the decision-making process for upward drug dosage modifications, especially in resource- and labor-limited settings.
• Clinical research for saliva-based therapeutic drug monitoring of linezolid.
  Yuki Inoue; Hitoshi Kashiwagi; Yuki Sato; Shunsuke Nashimoto; Tsutomu Endo; Masahiko Takahata; Miki Komatsu; Mitsuru Sugawara; Yoh Takekuma
  British journal of clinical pharmacology, 10 Oct. 2024, [Peer-reviewed], [International Magazine]
  English, Scientific journal, AIMS: Linezolid is primarily used to treat of methicillin-resistant Staphylococcus aureus and multidrug-resistant tuberculosis infections. Thrombocytopenia due to linezolid usage is a concern, and therapeutic drug monitoring has been reported to be effective in its prevention. Plasma concentrations provide valuable information for treatment decisions; however, collecting plasma samples can be burdensome for both patients and healthcare providers. Therefore, there is interest in saliva as an alternative for monitoring, considering its potential to replace plasma samples. METHODS: Patients hospitalized at Hokkaido University Hospital and Hokkaido Spinal Cord Injury Center between April 2022 and July 2024, who received oral or intravenous linezolid treatment, were enrolled. The concentrations of linezolid were simultaneously measured in plasma and saliva samples. We determined the concentration profiles of linezolid in the saliva and examined the correlation between saliva and plasma linezolid concentrations. RESULTS: Eighteen patients receiving linezolid were enrolled. The average of saliva/plasma (S/P) concentration ratios of linezolid were 1.018. A strong correlation was found between the salivary and plasma concentrations of linezolid (R = .833, P < .001). Notably, in patients receiving intravenous administration of linezolid, the correlation was even more pronounced (R = .885, P < .001). Additionally, when focusing on the S/P ratio of the trough concentrations in the morning and at night, the S/P ratios at night were much closer to 1.0. CONCLUSION: The concentrations of linezolid in plasma and saliva were similar, indicating their potential applicability in clinical settings. The monitoring of linezolid concentrations in saliva has been shown to be particularly suitable for patients receiving intravenous administration.
• Development of an Evaluation System Using Intestinal Organoids for Drug Efflux Transport Analysis by an Imaging Approach
  Chihiro Koseki; Takehiko Ishikawa; Yuki Sato; Mikiko Shimada; Yuki Yokoi; Kiminori Nakamura; Naoyuki Honma; Takanori Moriyama; Hitoshi Kashiwagi; Mitsuru Sugawara
  Journal of Pharmaceutical Sciences, Elsevier BV, Jun. 2024, [Peer-reviewed], [Lead author]
  English, Scientific journal
• Platelets Affect the Activity of Amino Acid Transporter SNAT4 in HuH-7 Human Hepatoma Cells.
  Hitoshi Kashiwagi; Yuki Sato; Shunsuke Nashimoto; Shungo Imai; Yoh Takekuma; Mitsuru Sugawara
  Biological & pharmaceutical bulletin, 47, 3, 652, 659, 2024, [Domestic magazines]
  English, Scientific journal, Platelets have been reported to exert diverse actions besides hemostasis and thrombus formation in the body. However, whether platelets affect transporter activity remains to be determined. In this study, we examined the effects of platelets on the activity of amino acid transporter system A, which is known to be changed by various factors, and we clarified the mechanism by which platelets affect system A activity. Among system A subtypes, we found that sodium-coupled neutral amino acid transporter (SNAT) 4 played a central role in the transport activity of system A in HuH-7 human hepatoma cells. Interestingly, platelets showed a biphasic effect on system A activity: activated platelet supernatants (APS) including the granule contents released from platelets downregulated system A activity at lower concentrations and the downregulation was suppressed at higher concentrations. The downregulation was due to a decrease in the affinity of SNAT4 for its substrate and not a decrease in the SNAT4 abundance on the plasma membrane. In addition, APS did not decrease the expression level of SNAT4 mRNA. On the other hand, platelets did not affect system A activity when the platelet suspension was added to HuH-7 cells. These results indicate that platelets indirectly affect the transport activity of system A by releasing bioactive substances but do not directly affect it by binding to HuH-7 cells.
• Comparison of the incidence of nausea and vomiting between linezolid and vancomycin using claims database: a retrospective cohort study.
  Takezo Tsutsumi; Shungo Imai; Kenji Momo; Hitoshi Kashiwagi; Yuki Sato; Mitsuru Sugawara; Yoh Takekuma
  International journal of clinical pharmacy, 29 Dec. 2023, [Peer-reviewed], [International Magazine]
  English, Scientific journal, BACKGROUND: Nausea and vomiting during linezolid therapy have been reported as part of safety analyses in clinical trials. We have previously examined the incidence of vomiting during linezolid therapy (18.1%). A previous study conducted at a single hospital showed low external validity. It is necessary to verify whether these results can be reproduced using generalizable data sources. AIM: To evaluate the incidence of nausea and vomiting during linezolid therapy compared with vancomycin using a Japanese claims database. METHOD: Patients administered linezolid or vancomycin were selected from the database between January 2005 and June 2017. The primary endpoint was the comparison of nausea and vomiting between the linezolid and vancomycin groups. We conducted propensity score matching (PSM) to adjust for patient characteristics. To assess risk factors for nausea and vomiting, logistic regression was conducted as the secondary endpoint. We defined nausea and vomiting as the first prescription of antiemetics during linezolid or vancomycin therapy as a surrogate endpoint. RESULTS: In total, 1215 patients were enrolled. After PSM, the number of patients in the linezolid and vancomycin groups was 241. Nausea and vomiting were observed in 11.2% and 5.0% of patients in the linezolid and vancomycin groups, respectively (p < 0.05). Linezolid administration was extracted as a risk factor for nausea and vomiting (odds ratio, 2.09; 95% confidence interval, 1.02-4.30). CONCLUSION: This study clarified the relationship between linezolid and nausea and vomiting using a Japanese claims database. Further studies are required to elucidate the unknown mechanisms of linezolid-induced nausea and vomiting.
• Quantitative analysis of communication changes in online medication counseling -Using the Roter Interaction Analysis System.
  Ayako Mori; Izumi Kato; Katsuya Narumi; Yoh Takekuma; Hitoshi Kashiwagi; Yuki Sato; Mitsuru Sugawara; Masaki Kobayashi
  Research in social & administrative pharmacy : RSAP, 04 Oct. 2023, [Peer-reviewed], [International Magazine]
  English, Scientific journal, BACKGROUND: Quantitative analysis and objective evaluation of communication play an important role in medical communication education. In the process of developing an online methodology for medication counseling practice, we felt the necessity of conducting a quantitative evaluation to enhance its effectiveness. OBJECTIVES: This study aimed to quantitatively evaluate the communication in each scenario to comprehensively identify the differences between face-to-face and online communication in medication counseling practicum. In addition, we examined how patient satisfaction changes between face-to-face and online interactions. METHODS: Face-to-face and online role-playing were conducted between simulated patients (SPs) and students acting as pharmacists, and their dialogues were videotaped. The utterances in each recorded dialogue were categorized and analyzed by the Roter interaction analysis system (RIAS). The Japanese version of the Medical Interview Satisfaction Scale (MISS-21J) responses of the SPs were analyzed for the patient satisfaction survey. RESULT: The results of the RIAS analysis revealed that the socio-emotional category appeared significantly more frequently in face-to-face communication, with more utterances that were more attuned to the feelings of the other person and more considerate of his or her feelings. The ratio of the number of utterances between students and SPs suggested that the communication was more interactive. CONCLUSION: Based on the respective communication tendencies may have led to higher satisfaction in face-to-face than in online patient satisfaction surveys, less anxiety about illness and medications, and easier trusting relationships. Since it is difficult to grasp the mood of the other party and to open up to them due to the lack of nonverbal information in online dialogue, it is necessary to be more conscious of conversations that capture the feelings of patients in online medication counseling.
• Monitoring Salivary Concentrations of Tedizolid and Linezolid Using Rats
  Yuki Inoue; Yuki Sato; Hitoshi Kashiwagi; Shunsuke Nashimoto; Mitsuru Sugawara; Yoh Takekuma
  European Journal of Drug Metabolism and Pharmacokinetics, Springer Science and Business Media LLC, 27 Jun. 2023, [Peer-reviewed]
  English, Scientific journal
• Use of Japanese big data from electronic medical records to investigate risk factors and identify their high-risk combinations for linezolid-induced thrombocytopenia.
  Yuki Inoue; Yoh Takekuma; Takayuki Miyai; Hitoshi Kashiwagi; Yuki Sato; Mitsuru Sugawara; Shungo Imai
  European journal of clinical pharmacology, 30 Jan. 2023, [Peer-reviewed], [International Magazine]
  English, Scientific journal, PURPOSE: Thrombocytopenia is a major event associated with linezolid (LZD) therapy. Factors affecting LZD-induced thrombocytopenia (LIT) have been reported in previous studies. However, several issues pertaining to LIT have not yet been clarified. In the present study, we used Japanese big data to investigate associated factors and their high-risk combinations that influence LIT. METHODS: Patients administered LZD between May 2006 and October 2020 were included in this study. LIT was defined as either a 30% or more reduction from the baseline platelets or platelet values of < 100,000/µL. We evaluated factors affecting LIT and combinations of factors that alter LIT risk according to a decision tree (DT) analysis, a typical machine learning method. RESULTS: We successfully enrolled 1399 patients and LIT occurred in 44.7% of the patients (n = 626). We classified the laboratory data on renal function, LZD duration, age, and body weight (BW) into smaller categories. The results of multivariate analysis showed that prolonged LZD therapy, BW < 45 kg, estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m2, and dialysis were risk factors for LIT. The DT analysis revealed that the highest risk was a combination of LZD duration ≥ 14 days and eGFR < 30 mL/min/1.73 m2. CONCLUSIONS: The present study extracted four risk factors and identified high-risk combinations for LIT. Patients with these risk factors should be closely monitored.
• Effects of Body Composition on Renal Function Estimates in Older Patients.
  Soyoko Kaburaki; Shungo Imai; Hitoshi Kashiwagi; Yuki Sato; Mitsuru Sugawara; Yoh Takekuma
  Biological & pharmaceutical bulletin, 46, 11, 1609, 1618, 2023, [Peer-reviewed], [Domestic magazines]
  English, Scientific journal, The modified Cockcroft-Gault (CG) equation, previously developed for an aged-oriented cohort, was validated in a newly obtained dataset. Estimates of creatinine clearance (CCr) using this equation were found to be more accurate than those determined using the conventional CG equation, particularly for patients exceeding 65 years of age. We identified a subset of patients in this cohort whose estimates were inadequate. Using statistical analysis, we found that the deviation from estimates was attributed to a decreased albumin level. In addition, we determined a reduced albumin cutoff value for the modified CG equation to obtain a good estimate. Univariate linear regression analysis was applied to measure the CCr in this cohort and identify parameters related to body composition, and we found that extracellular water (ECW)/total body water (TBW) and body fat (%) were relevant. Using measured values of ECW/TBW and body fat (%), a multivariate linear regression (MLR) estimating equation was developed based on the modified CG equation. This equation was applied to a cohort over 65 years of age, and it was found that a good estimate was obtained for older patients with low albumin levels. Thus, we propose a flow diagram that illustrates conditions for selecting an appropriate estimating equation from among the CG, modified CG, and MLR equations.
• Survey Targeting Community Pharmacists regarding Consultation Requests from Patients Owing to Media Reports on ”Dangers of Drugs”
  今井俊吾; 今井俊吾; 阿部真也; 松井洸; 柏木仁; 佐藤夕紀; 武隈洋; 吉町昌子; 菅原満; 菅原満; 菅原満
  医薬品情報学, 24, 2, 75, 87, (一社)日本医薬品情報学会, Aug. 2022, [Peer-reviewed]
  Japanese
• 週刊誌に掲載された「危ないクスリ」に関する情報の整理とその適切性評価
  今井 俊吾; 柏木 仁; 佐藤 夕紀; 武隈 洋; 菅原 満
  医薬品情報学, 24, 1, 1, 10, (一社)日本医薬品情報学会, May 2022, [Peer-reviewed]
  Japanese, Scientific journal, 週刊誌に記載された処方箋の「危険性」に関する記事の適切性を、オーストラリアで開発されたマスメディアによる医療・健康記事の質を評価するための指標である「メディアドクター指標」を処方箋等に適用できるよう改変したものを用いて明らかにすることを目的に、2018年1月1日から2021年5月24日までに発行された「週刊朝日」「サンデー毎日」など週刊誌10誌を対象に、「薬剤名や薬効分類を特定可能」かつ「当該薬剤・薬効分類におけるヒトに対する具体的な副作用・有害事象に関して記述」している記事19本(週刊誌6誌)を2名の評価者により評価した。その結果、19本の記事のうち10本はB誌に掲載されたもので、計179種類の薬剤(薬効分類で34種類)の危険性について言及されていた。対象となった19本の記事の内容を9項目について評価者2人が評価した結果、11本で2名とも不満足とした評価項目が半数を超えていた。
• 週刊誌に掲載された「危ないクスリ」に関する情報の整理とその適切性評価
  今井 俊吾; 柏木 仁; 佐藤 夕紀; 武隈 洋; 菅原 満
  医薬品情報学, 24, 1, 1, 10, (一社)日本医薬品情報学会, May 2022, [Peer-reviewed]
  Japanese, 週刊誌に記載された処方箋の「危険性」に関する記事の適切性を、オーストラリアで開発されたマスメディアによる医療・健康記事の質を評価するための指標である「メディアドクター指標」を処方箋等に適用できるよう改変したものを用いて明らかにすることを目的に、2018年1月1日から2021年5月24日までに発行された「週刊朝日」「サンデー毎日」など週刊誌10誌を対象に、「薬剤名や薬効分類を特定可能」かつ「当該薬剤・薬効分類におけるヒトに対する具体的な副作用・有害事象に関して記述」している記事19本(週刊誌6誌)を2名の評価者により評価した。その結果、19本の記事のうち10本はB誌に掲載されたもので、計179種類の薬剤(薬効分類で34種類)の危険性について言及されていた。対象となった19本の記事の内容を9項目について評価者2人が評価した結果、11本で2名とも不満足とした評価項目が半数を超えていた。
• 機械学習を活用した定常状態のAUC400-600mg・h/Lを目標とするバンコマイシン投与量推定モデルの構築
  宮井 貴之; 今井 俊吾; 吉村 理恵; 柏木 仁; 佐藤 夕紀; 上野 英文; 武隈 洋; 菅原 満
  TDM研究, 39, 2, 128, 128, (一社)日本TDM学会, May 2022, [Peer-reviewed]
  Japanese, Scientific journal
• Development of a Method of Liquid Chromatography Coupled with Tandem Mass Spectrometry for Simultaneous Determination of Linezolid and Tedizolid in Human Plasma.
  Yuki Sato; Yoh Takekuma; Takayuki Daisho; Hitoshi Kashiwagi; Shungo Imai; Mitsuru Sugawara
  Biological & pharmaceutical bulletin, 45, 4, 421, 428, Apr. 2022, [Peer-reviewed], [Lead author], [Domestic magazines]
  English, Scientific journal, It is important to select appropriate antibiotics for infection control. Linezolid and tedizolid are newly developed and synthesized oxazolidinone antibacterial agents. It has been pointed out that there is a relationship between a high plasma concentration of the target drug and incidence of adverse effects, although it has been reported that neither linezolid nor tedizolid requires dose adjustment according to renal function. Due to the high incidence of adverse effects, both are often switched. Precise plasma concentration control by therapeutic drug monitoring (TDM) is desirable for reducing the adverse effects of both drugs and obtaining a better therapeutic effect. In this study, we aimed to establish a method for simultaneous quantification of linezolid and tedizolid in human plasma using LC coupled with tandem mass spectrometry. Sample preparation was performed by a simple operation with acetonitrile. Linezolid and tedizolid were separated by an octadecylsilyl column using a gradient elution of acetonitrile in aqueous 0.1% formic acid solution and were detected in the positive ion electrospray mode with multiple reaction monitoring. Quantification of linezolid and tedizolid ranged from 0.5 to 50 and 0.5 to 20 µg/mL, respectively. The intra-day and inter-day precision and accuracy of data were assessed and found to be acceptable. The developed method was successfully applied to measurement of the concentrations of linezolid and tedizolid. This simple method, which can simultaneously quantify both drug concentrations for daily TDM, could contribute to safer treatment of patients.
• Factors affecting creatine phosphokinase elevation during daptomycin therapy using a combination of machine learning and conventional methods.
  Shungo Imai; Hitoshi Kashiwagi; Yuki Sato; Takayuki Miyai; Mitsuru Sugawara; Yoh Takekuma
  British journal of clinical pharmacology, 88, 3, 1211, 1222, Mar. 2022, [Peer-reviewed], [International Magazine]
  English, Scientific journal, AIMS: Musculoskeletal toxicity is a typical side effect of daptomycin (DAP). However, the risk factors have not been well established. Here, we aimed to identify independent factors affecting DAP-induced musculoskeletal toxicity using a combination of machine learning and conventional statistical methods. METHODS: A population-based, retrospective, observational cohort study was conducted using the Japanese electronic medical record database. Patients who received DAP between October 2011 and December 2020 were enrolled. Two definitions of musculoskeletal toxicity were employed: (1) elevation of creatine phosphokinase (CPK) value more than twice from baseline and >200 IU/L, and (2) >1000 IU/L. First, multiple logistic regression analyses (a conventional statistical method) were performed to identify independent factors affecting CPK elevation. Then, decision tree analyses, a machine learning method, were performed to detect combinations of factors that change CPK elevation risk. RESULTS: Of the 2970 patients who received DAP, 706 were included. Elevation of CPK values >200 IU/L and >1000 IU/L occurred in 83 (11.8%) and 17 (2.41%) patients, respectively. In multiple logistic regression analysis, baseline CPK value and concomitant use of hydrophobic statins were commonly extracted as independent factors affecting each CPK elevation, but concomitant use of hydrophilic statins was not. In decision tree analysis, patients who received hydrophobic statins and had high baseline CPK values were classified into the high-risk group. CONCLUSION: Our novel approach revealed new risk factors for CPK elevation. Our findings suggest that high-risk patients require frequent CPK monitoring.
• Using Japanese big data to investigate novel factors and their high-risk combinations that affect vancomycin-induced nephrotoxicity.
  Shungo Imai; Shota Kadomura; Takayuki Miyai; Hitoshi Kashiwagi; Yuki Sato; Mitsuru Sugawara; Yoh Takekuma
  British journal of clinical pharmacology, 88, 7, 3241, 3255, 01 Feb. 2022, [Peer-reviewed], [International Magazine]
  English, Scientific journal, AIMS: Several factors related to vancomycin-induced nephrotoxicity (VIN) have not yet been clarified. In the present study, we used Japanese big data to investigate novel factors and their high-risk combinations that influence VIN. METHODS: We employed a large Japanese electronic medical record database and included patients who had been administered intravenous vancomycin between June 2000 and December 2020. VIN was defined as an increase in serum creatinine ≥0.5 mg/dL or 1.5-fold higher than the baseline. The outcomes were: (1) factors affecting VIN that were identified using multiple logistic regression analysis, and (2) combinations of factors that affect the risk of VIN according to a decision tree analysis, which is a typical machine learning method. RESULTS: Of the 7306 patients that were enrolled, VIN occurred in 14.2% of them (1035). A multivariate analysis extracted 22 variables as independent factors. Concomitant ramelteon use (odds ratio 0.701, 95% confidence interval 0.512-0.959), ward pharmacy service (0.741, 0.638-0.861), duration of VCM < 7 days (0.748, 0.623-0.899) and trough concentrations 10-15 mg/L (0.668, 0.556-0.802) reduce the risk of VIN. Meanwhile, concomitant piperacillin-tazobactam use (2.056, 1.754-2.409) and piperacillin use (2.868, 1.298-6.338) increase the risk. The decision tree analysis showed that a combination of vancomycin trough concentrations ≥20 mg/L and concomitant piperacillin-tazobactam use was associated with the highest risk. CONCLUSIONS: We revealed that the concomitant ramelteon use and ward pharmacy service may decrease the risk of VIN, while the concomitant use of not only piperacillin-tazobactam but also piperacillin may increase the risk.
• Investigation of the risk factors of vomiting during linezolid therapy: a retrospective observational study.
  Takezo Tsutsumi; Shungo Imai; Hitoshi Kashiwagi; Yuki Sato; Mitsuru Sugawara; Yoh Takekuma
  European journal of clinical pharmacology, 78, 2, 279, 286, Feb. 2022, [Peer-reviewed], [International Magazine]
  English, Scientific journal, PURPOSE: Some clinical studies have reported the occurrence of nausea and vomiting with linezolid (LZD) administration. However, no studies have evaluated nausea and vomiting as primary endpoints. In a previous study, we noted a possible relationship between LZD and vomiting, but risk factors were not identified. Therefore, the aim of the present study was to identify them. METHODS: Patients who received LZD 600 mg twice daily at Hokkaido University Hospital from September 2008 to April 2019 were enrolled in this retrospective observational study. Patient characteristics, concomitant medications, laboratory data, and the occurrence of vomiting were obtained from electronic medical records. Logistic regression analysis was performed to identify risk factors for vomiting, including age, sex, body weight, concomitant medications, and surgeries. RESULTS: A total of 496 patients were included in this study, of which 90 experienced vomiting. By multivariate logistic regression analysis, female sex (adjusted odds ratio [aOR], 2.69; 95% confidence interval [CI], 1.62-4.47), ≥ 10 days of LZD administration (aOR, 2.57; CI, 1.46-4.50), and hyponatraemia (aOR, 2.96; CI, 1.72-5.10) were identified as independent risk factors for vomiting; administration of serotonergic agents (aOR, 0.23; CI, 0.07-0.82) was negatively associated. CONCLUSIONS: This study is the first to successfully identify risk factors for LZD-induced vomiting. Careful monitoring of patients with these risk factors may lead to safer and sustainable LZD administration.
• Machine Learning-Based Model for Estimating Vancomycin Maintenance Dose to Target the Area under the Concentration Curve of 400-600 mg·h/L in Japanese Patients.
  Takayuki Miyai; Shungo Imai; Eri Yoshimura; Hitoshi Kashiwagi; Yuki Sato; Hidefumi Ueno; Yoh Takekuma; Mitsuru Sugawara
  Biological & pharmaceutical bulletin, 45, 9, 1332, 1339, 2022, [Peer-reviewed], [Domestic magazines]
  English, Scientific journal, In therapeutic drug monitoring of vancomycin (VCM), the area under the concentration-time curve (AUC) is related to clinical efficacy and toxicity. Determining the maintenance for patient is necessary since VCM concentrations are affected by factors such as renal function. We constructed a machine learning-based model to estimate the maintenance dose to target an AUC of 400-600 mg⋅h/L in each combination of patient's factors. This retrospective observational study was conducted at two hospitals. Patients who received VCM intravenously with measured trough and another point (e.g., peak) concentrations within the November 2011 to March 2019 period were enrolled. We extracted the factors that affect VCM concentration and constructed a decision tree model using a classification and regression tree algorithm. Of the 1380 patients, 822 were included. Training data were split up to four times and included 24 subgroups. The average corrected VCM daily doses ranged 17.6-59.4 mg/kg. Estimated glomerular filtration rate, age, and body mass index were selected as predictive variables that affected the recommended daily dose. In the validation data, our model had slightly higher proportions of AUC of 400-600 mg⋅h/L than other nomograms. However, our model was based only on limited patients. Thus, further clinical studies are needed to develop a general-purpose model in the future. We successfully constructed a model that recommends VCM maintenance daily doses with AUC of 400-600 mg⋅h/L for each combination of independent variables. Our model has the potential for application as a simple decision-making tool for medical staff.
• [Development of an Online Role-play-based Medical Interview Training Method for Fourth-year Pharmacy Students].
  Ayako Mori; Izumi Kato; Hitoshi Kashiwagi; Shungo Imai; Katsuya Narumi; Yuki Sato; Ayako Furugen; Yuma Yamada; Masaki Kobayashi
  Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 142, 6, 661, 674, 2022, [Peer-reviewed], [Domestic magazines]
  Japanese, Scientific journal, With the coronavirus disease 2019 pandemic, businesses are rapidly expanding their online practices, and the online medical care system has been established and is growing. The field of pharmacy education is also looking for ways to conduct practical online training. Hence, we developed an online role-play-based medical interview training method for fourth-year pharmacy students. The purpose of this study was to describe in detail this method and to clarify the effect of online on medical interviewing practice. The training sessions were conducted using video teleconferencing software. Two settings were used for the role-play scenarios: the pharmacy and hospital. To evaluate the effectiveness of the sessions, a questionnaire was sent to the students, and the results were analyzed using text mining. The most important requirement for successfully conducting the interviews was a stable voice connection, and we reduced audio interruptions and delays by connecting the host personal computer to a wired local area network. We also solved the problem of howling when multiple terminals were installed in the same room by muting all devices in the room. Results of the analysis of the questionnaires suggested that students were more tense online. We also found that students perceived a difference between online and face-to-face interviews in terms of eye contact and the presentation of documents. In this way, we succeeded in conducting smooth online role-playing sessions while taking countermeasures against infection. In the future, it will be necessary to devise nonverbal communication methods and digital methods of presenting the training material.
• Prescription and Therapeutic Drug Monitoring Status of Valproic Acid among Patients Receiving Carbapenem Antibiotics: A Preliminary Survey Using a Japanese Claims Database
  Shungo Imai; Kenji Momo; Hitoshi Kashiwagi; Yuki Sato; Takayuki Miyai; Mitsuru Sugawara; Yoh Takekuma
  Annals of Clinical Epidemiology, 4, 1, 6, 10, Society for Clinical Epidemiology, 2022, [Peer-reviewed]
  Scientific journal
• プロトンポンプ阻害薬使用患者においてNSAIDs又は抗菌薬の併用が急性腎障害発症に及ぼす影響
  幾田 慧子; 中川 俊作; 百 賢二; 米澤 淳; 糸原 光太郎; 佐藤 夕紀; 今井 哲司; 中川 貴之; 松原 和夫; 寺田 智祐
  薬剤疫学, 26, Suppl., S117, S118, (一社)日本薬剤疫学会, Nov. 2021
  Japanese
• Effects of piperacillin/tazobactam or cefepime on folinate dose in patients receiving high-dose methotrexate: A retrospective cohort study using Japanese administrative claims data.
  Shota Kadomura; Shungo Imai; Kenji Momo; Yuki Sato; Hitoshi Kashiwagi; Tatsuya Itoh; Mitsuru Sugawara; Yoh Takekuma
  Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 28, 7, 10781552211034703, 10781552211034703, 18 Oct. 2021, [Peer-reviewed], [International Magazine]
  English, Scientific journal, INTRODUCTION: Delayed methotrexate (MTX) clearance with the co-administration of piperacillin/tazobactam (PIPC/TAZ) has been reported. Penicillins have been associated with reduced MTX clearance but the evidence is limited. There are no cases described with cefepime but penicillins are listed as interacting with MTX. We aimed to reveal whether the co-administration of PIPC/TAZ or CFPM affects MTX clearance using data from an administrative database. METHODS: We used data from the JMDC database, a large insurance claims database constructed in Japan. We included patients who were prescribed PIPC/TAZ or CFPM between days 1 and 3 in high-dose MTX (HD-MTX). We compared one co-administration episode (with PIPC/TAZ or CFPM) to one control episode (without), as a match-control study of two different episodes in the same patient. The primary outcomes were the duration and cumulative dose of leucovorin (LV) as a surrogate indicator of delayed MTX clearance. RESULTS: Three patients who were co-administered PIPC/TAZ and 16 patients who were co-administered CFPM with HD-MTX were included. In the PIPC/TAZ group, the duration and the cumulative doses of LV were similar in co-administration and control episode (median 3.0 vs. 3.0 days and 288.0 vs. 219.0 mg). In the CFPM group, the duration and the cumulative doses of LV were not significantly different in co-administration and control episode (3.0 vs. 4.0 days and 169.5 vs. 258.0 mg). CONCLUSIONS: Our findings revealed that PIPC/TAZ did not necessarily cause a delay in MTX clearance during HD-MTX therapy. Moreover, the co-administration of CFPM with HD-MTX did not affect MTX clearance.
• A cross-sectional survey of hospitalization and blood tests implementation status in patients who received tolvaptan under 75 years of age using a Japanese claims database.
  Shungo Imai; Kenji Momo; Hitoshi Kashiwagi; Yuki Sato; Takayuki Miyai; Mitsuru Sugawara; Yoh Takekuma
  Expert opinion on drug safety, 20, 10, 1257, 1266, Oct. 2021, [Peer-reviewed], [International Magazine]
  English, Scientific journal, BACKGROUND: Hypernatremia and liver injury are typical adverse effects of tolvaptan. Therefore, hospitalization and frequent monitoring of serum sodium concentration and liver function are necessary for tolvaptan initiation. We performed a cross-sectional survey to evaluate these situations. RESEARCH DESIGN AND METHODS: We employed the Japanese claims database, which contains data of patients aged < 75 years. Patients who were newly prescribed tolvaptan for fluid accumulation induced by chronic heart failure (FA-CHF) or liver cirrhosis (FA-LC) from January 2011 to June 2017 were included. We evaluated the hospitalization status and implementation of serum sodium and liver function tests in the evaluation period, based on the Japanese package insert. RESULTS: Of 1,173 patients, 347 and 117 were enrolled in FA-CHF and FA-LC groups, respectively. Among them, 10.7% (FA-CHF group) and 5.13% (FA-LC group) were prescribed tolvaptan without hospitalization. In the FA-CHF group, 11.0% and 17.6% did not undergo serum sodium and liver function tests even once in the evaluation period, respectively, compared with 12.0% and 12.8% in the FA-LC group. CONCLUSIONS: Our results highlight the deviation from Japanese package insert recommendations. This approach can be applied to other drugs and provides important perspectives on pharmacovigilance research.
• Implementation Status of Liver Function Tests for Monitoring Benzbromarone-Induced Hepatotoxicity: An Epidemiological Survey Using the Japanese Claims Database.
  Shungo Imai; Yasuyuki Nasuhara; Kenji Momo; Hiromitsu Oki; Hitoshi Kashiwagi; Yuki Sato; Takayuki Miyai; Mitsuru Sugawara; Yoh Takekuma
  Biological & pharmaceutical bulletin, 44, 10, 1499, 1505, Oct. 2021, [Peer-reviewed], [Domestic magazines]
  English, Scientific journal, A major adverse effect of benzbromarone is hepatotoxicity. Therefore, periodic liver function tests are required at least for the first 6 months of benzbromarone administration. However, it is not clear whether the relevant blood tests are implemented appropriately. Here, we performed a cross-sectional survey of the implementation status of liver function tests in patients who were newly prescribed benzbromarone, using the Japanese large claims database. Male patients who were newly prescribed benzbromarone from January 2010 to December 2016 were included. We targeted patients who continued benzbromarone during the observation period (up to 180 d from the start of administration). The primary endpoint was the proportion of patients in whom periodic liver function tests were implemented. A periodic liver function test was defined as one or more liver function tests performed during both 1-90 and 91-180 d of initial benzbromarone administration. We labeled the tests as a "periodic test" or "non-periodic test" based on whether periodic liver function tests were performed or not, respectively. Furthermore, factors influencing non-periodic test were analyzed. Periodic testing was implemented only in 28.7% of patients. Additionally, factors such as number of hospital beds ≤19 (compared to 100-199 beds) and duration of the first prescription of benzbromarone were associated with non-periodic testing. Our study revealed that periodic liver function tests are not performed sufficiently in Japan. Thus, clinicians prescribing benzbromarone should be educated about the test. Our blood-test-based approach should be applied to other drugs and countries in future research.
• 大規模レセプトデータベースを用いたボリコナゾールの治療薬物モニタリング実施に関する実態調査
  宮井 貴之; 今井 俊吾; 百 賢二; 柏木 仁; 佐藤 夕紀; 菅原 満; 武隈 洋
  TDM研究, 38, 3, 39, 48, (一社)日本TDM学会, Sep. 2021, [Peer-reviewed]
  Japanese
• cAMP Signaling Pathway Prevents Dasatinib-Induced Vascular Hyperpermeability.
  Tsuyoshi Aoyama; Hiroki Kuriyama; Yuki Sato; Shungo Imai; Hitoshi Kashiwagi; Mitsuru Sugawara; Yoh Takekuma
  Biological & pharmaceutical bulletin, 44, 8, 1101, 1110, Aug. 2021, [Peer-reviewed], [Domestic magazines]
  English, Scientific journal, Dasatinib is a first-line pharmacotherapeutic treatment for chronic myeloid leukemia (CML). It is more effective than traditional treatments but causes adverse effects such as pleural effusion that limits its effective treatment cycle. Since pleural effusion is caused by vascular hyperpermeability and causes discontinuation of treatment with dasatinib, it is important to explore the mechanism of pleural effusion caused by dasatinib and how to prevent it. In this study, we investigated how dasatinib increase vascular permeability, and how it can be prevented. Cytotoxicity was observed in vascular endothelial cells or epithelial cells were exposed to high concentrations of dasatinib. Thus, it was observed in vascular endothelial cells such as human umbilical vascular endothelial cell (HUVEC). Vascular endothelial (VE)-cadherin is one of the important factors that control vascular permeability. When VE-cadherin expression decreases, vascular permeability increases, but it did not change with tyrosine kinase inhibitor exposure. Monolayer permeability significantly increased only with high concentration of dasatinib, but this increase was prevented by cAMP activation. Furthermore, dasatinib affects the cell morphology of HUVEC, with increased inter celluar space compared to control and bosutinib, which were also attenuated by cAMP activation. Dasatinib significantly affected permeability control of vascular endothelial cells compared to bosutinib and imatinib. These results indicated that the cAMP signaling pathway may be involved in the pleural effusion caused by dasatinib in CML patients.
• Investigation of the Real-World Situation and Risk Factors Associated with Olanzapine Prescribed to Diabetes Patients by Using a Japanese Claims Database.
  Shinsuke Yamashita; Shungo Imai; Kenji Momo; Hitoshi Kashiwagi; Yuki Sato; Mitsuru Sugawara; Yoh Takekuma
  Biological & pharmaceutical bulletin, 44, 8, 1151, 1155, Aug. 2021, [Peer-reviewed], [Domestic magazines]
  English, Scientific journal, Olanzapine is effective for schizophrenia management; however, it is contraindicated in diabetes patients. In addition, olanzapine is useful for treating nausea and vomiting, such as in the case of chemotherapy-induced nausea and vomiting (CINV). Therefore, we hypothesized that the contraindicated prescription of olanzapine likely occurs among cancer patients with diabetes, especially by non-psychiatric physicians. Hence, we conducted a nationwide survey to elucidate the situation of such contraindicated prescriptions and the associated risk factors. We extracted the data of patients who were newly prescribed olanzapine between April 2015 and March 2017 from the health insurance claims database developed by JMDC, Inc., Tokyo. The patients who were prescribed contraindicated olanzapine were defined as those who were prescribed olanzapine after a diagnosis of diabetes and diabetes drug prescription. In all, the data of 7181 patients were analyzed. We evaluated the proportion of diabetes patients who were prescribed contraindicated olanzapine from among those who were prescribed olanzapine. Furthermore, we investigated the background of patients who were prescribed olanzapine for information such as olanzapine prescribers and history of cancer chemotherapy. In all, 100 diabetes patients (1.39%) were prescribed olanzapine. In these patients, the frequency of olanzapine prescription was higher by non-psychiatry/neurology physicians than by psychiatry/neurology physicians (3.25 and 0.85%, respectively). Additionally, all olanzapine prescriptions in cancer chemotherapy-treated diabetes patients were issued by non-psychiatry/neurology physicians. Thus, our study revealed there were diabetes patients who were prescribed olanzapine. Additionally, olanzapine for CINV management was more likely to be a contraindicated prescription.
• An imaging approach for determining the mechanism of enhancement of intestinal absorption of an L-theanine supplement.
  Yuki Sato; Kazuki Yamaguchi; Mikako Ogawa; Yoh Takekuma; Mitsuru Sugawara
  PloS one, 16, 6, e0253066, Jun. 2021, [Peer-reviewed], [Lead author], [International Magazine]
  English, Scientific journal, BACKGROUND & OBJECTIVE: Theanine (L-glutamylethylamide) contained in green tea is a functional food component that has been attracting attention due to its relaxation effect. It was shown that the ingredients added to the theanine formulations increased the absorption of theanine. If this mechanism can be elucidated, it would be possible to contribute to development of evidence-based formulations. In this study, we investigated the effect of ingredients in the formulations on the absorption of theanine in detail. MAIN METHODS: After oral administration of a mixture of theanine and additional components to Wistar rats the plasma concentration was determined by an HPLC and the pharmacokinetic parameters were calculated. In addition, a new system for evaluating intestinal blood flow was developed since the involvement of intestinal blood flow was considered as a factor that increased absorption of theanine. KEY FINDINGS: Plasma concentration of theanine increased significantly in the combined use group with eight ingredients containing piperine as compared with theanine only group. Piperine would increase theanine absorption by increased blood flow, not an inhibition of metabolism. We succeeded to develop a visual and quantitative system to evaluate the effect of these ingredients directly including piperine on the intestinal blood flow using indocyanine green while maintaining physiological conditions. SIGNIFICANCE: Increased intestinal blood flow by these ingredients including piperine enhanced the absorption of theanine. Other mechanisms may also be considered as the mechanism by which theanine absorption is increased in addition to increased blood flow.
• 薬局薬剤師による「患者への聞き取り」に基づいて実施された疑義照会の実態解明と医療安全への貢献度評価
  今井 俊吾; 難波 正志; 柏木 仁; 佐藤 夕紀; 武隈 洋; 菅原 満
  薬局薬学, 13, 1, 68, 78, (一社)日本薬局学会, Apr. 2021, [Peer-reviewed]
  Japanese, Scientific journal
• Association of proton pump inhibitors and concomitant drugs with risk of acute kidney injury: a nested case-control study.
  Keiko Ikuta; Shunsaku Nakagawa; Kenji Momo; Atsushi Yonezawa; Kotaro Itohara; Yuki Sato; Satoshi Imai; Takayuki Nakagawa; Kazuo Matsubara
  BMJ open, 11, 2, e041543, 15 Feb. 2021, [Peer-reviewed], [International Magazine]
  English, Scientific journal, OBJECTIVES: This study aimed to assess whether the combined use of proton pump inhibitors (PPIs) with non-steroidal anti-inflammatory drugs (NSAIDs) or antibiotics (penicillins, macrolides, cephalosporins or fluoroquinolones) was associated with an increased risk of acute kidney injury (AKI). DESIGN: A nested case-control study. SETTING: A health insurance claims database constructed by the Japan Medical Data Center. PARTICIPANTS: Patients were eligible if they were prescribed a PPI, NSAID and antibiotic at least once between January 2005 and June 2017. The patients who were new PPI users and did not have any history of renal diseases before cohort entry were included (n=219 082). The mean age was 45 and 44% were women. INTERVENTIONS: Current use of PPIs, NSAIDs, or antibiotics. PRIMARY OUTCOME MEASURES: Acute kidney injury. RESULTS: During a mean follow-up of 2.4 (SD, 1.7) years, 317 cases of AKI were identified (incidence rate of 6.1/10 000 person-years). The current use of PPIs was associated with a higher risk of AKI compared with past PPI use (unadjusted OR, 4.09; 95% CI, 3.09 to 5.44). The unadjusted ORs of AKI for the current use of PPIs with NSAIDs, cephalosporins and fluoroquinolones, compared with the current use of PPIs alone, were 3.92 (95% CI, 2.40 to 6.52), 2.57 (1.43 to 4.62) and 3.08 (1.50 to 6.38), respectively. The effects of concurrent use of PPIs with NSAIDs, cephalosporins or fluoroquinolones remain significant in the adjusted model. The analyses on absolute risk of AKI confirmed the results from the nested case-control study. CONCLUSIONS: Concomitant use of NSAIDs with PPIs significantly increased the risk for AKI. Moreover, the results suggested that concomitant use of cephalosporins or fluoroquinolones with PPIs was associated with increased risk of incident AKI.
• A new system to evaluate characteristics of Niemann-Pick C1 Like 1-mediated cholesterol transport using Xenopus laevis oocytes.
  Shunsuke Nashimoto; Saori Yagi; Naoki Takeda; Miku Nonaka; Yoh Takekuma; Mitsuru Sugawara; Yuki Sato
  Biochimica et biophysica acta. Biomembranes, 1863, 2, 183508, 183508, 01 Feb. 2021, [Peer-reviewed], [Last author, Corresponding author], [International Magazine]
  English, Scientific journal, Niemann-Pick C1 Like 1 (NPC1L1) is known to be involved in the intestinal absorption of cholesterol. For evaluating the function of NPC1L1, cell lines such as Caco-2, Madin-Darby canine kidney (MDCK) II, and McA-RH7777 have been used in previous studies, but the detailed molecular mechanism of transport has not been elucidated. In this study, the characteristics of cholesterol transport via NPC1L1 were investigated using a Xenopus laevis oocyte expression system in addition to a conventional cell line with stable expression. The transport activity of cholesterol uptake was increased in NPC1L1-overexpressed MDCK cells compared with that in mock cells, but MDCK cells expressed endogenous NPC1L1 and had high cholesterol transport activity. On the other hand, cRNA-injected oocytes expressed NPC1L1 after culturing for 5-6 days. The transport activity of cholesterol uptake was increased in NPC1L1 cRNA-injected oocytes compared with that in water-injected oocytes. In addition, the uptake of cholesterol was decreased in the presence of ezetimibe, an NPC1L1 inhibitor, in cRNA-injected oocytes but not in control oocytes, indicating that endogenous NPC1L1 is not expressed in oocytes. Furthermore, cholesterol uptake was substantially decreased in NPC1L1 L216A cRNA-injected oocytes compared with that in NPC1L1 cRNA-injected oocytes, indicating that leucine at position 216 of NPC1L1 is important for cholesterol transport and that an oocyte expression system is useful for mutant analysis. These results indicate that the oocyte expression system is useful for evaluating the characteristics of NPC1L1-mediated cholesterol transport and may contribute to the elucidation of the detailed molecular mechanism of cholesterol transport via NPC1L1.
• A Risk Prediction Flowchart of Vancomycin-Induced Acute Kidney Injury to Use When Starting Vancomycin Administration: A Multicenter Retrospective Study.
  Takayuki Miyai; Shungo Imai; Hitoshi Kashiwagi; Yuki Sato; Shota Kadomura; Kenji Yoshida; Eri Yoshimura; Toshiaki Teraya; Takashi Tsujimoto; Yukari Kawamoto; Tatsuya Itoh; Hidefumi Ueno; Yoshikazu Goto; Yoh Takekuma; Mitsuru Sugawara
  Antibiotics (Basel, Switzerland), 9, 12, 920, 18 Dec. 2020, [Peer-reviewed], [International Magazine]
  English, Scientific journal, We previously constructed a risk prediction model of vancomycin (VCM)-associated nephrotoxicity for use when performing initial therapeutic drug monitoring (TDM), using decision tree analysis. However, we could not build a model to be used at the time of initial administration due to insufficient sample size. Therefore, we performed a multicenter study at four hospitals in Japan. We investigated patients who received VCM intravenously at a standard dose from the first day until the initial TDM from November 2011 to March 2019. Acute kidney injury (AKI) was defined according to the criteria established by the "Kidney disease: Improving global outcomes" group. We extracted potential risk factors that could be evaluated on the day of initial administration and constructed a flowchart using a chi-squared automatic interaction detection algorithm. Among 843 patients, 115 (13.6%) developed AKI. The flowchart comprised three splitting variables (concomitant drugs (vasopressor drugs and tazobactam/piperacillin) and body mass index ≥ 30) and four subgroups. The incidence rates of AKI ranged from 9.34 to 36.8%, and they were classified as low-, intermediate-, and high-risk groups. The accuracy of flowchart was judged appropriate (86.4%). We successfully constructed a simple flowchart predicting VCM-induced AKI to be used when starting VCM administration.
• Transport via Niemann-Pick C1 Like 1 contributes to the intestinal absorption of ubiquinone.
  Shunsuke Nashimoto; Yuto Takekawa; Yoh Takekuma; Mitsuru Sugawara; Yuki Sato
  Drug metabolism and pharmacokinetics, 35, 6, 527, 533, Dec. 2020, [Peer-reviewed], [Last author, Corresponding author], [International Magazine]
  English, Scientific journal, Ubiquinone, which is a component in the electron-transport systems of mitochondria, is essential for various activities related to energy metabolism, but the detailed absorption mechanism of ubiquinone is not clear. On the other hand, Niemann-Pick C1 Like 1 (NPC1L1) is involved in the intestinal absorption of fat-soluble components such as cholesterol. In this study, we investigated whether the intestinal absorption of ubiquinone was transported by NPC1L1 as is cholesterol. In this study, coenzyme q10 (CoQ10) and coenzyme q9 (CoQ9) were used as models of ubiquinone. The transport activity of ubiquinone was increased significantly in NPC1L1-overexpressed Madin-Darby canine kidney (MDCK) cells compared with that in pMAM2-BSD vector-transfected MDCK cells and the uptake of ubiquinone was decreased in the presence of ezetimibe, an inhibitor of NPC1L1. These results indicate that NPC1L1 mediates the transport of ubiquinone. Furthermore, to clarify the effect of NPC1L1 on the intestinal absorption of CoQ10, emulsified CoQ10 was orally administered to Wistar rats, and the plasma concentration was measured. The plasma concentration of CoQ10 was significantly decreased by coadministration of ezetimibe and CoQ10 compared to that with administration of only CoQ10. This result indicates that the intestinal absorption of CoQ10 is mediated by NPC1L1.
• Comparison of interactions between warfarin and cephalosporins with and without the N-methyl-thio-tetrazole side chain.
  Shungo Imai; Shota Kadomura; Kenji Momo; Hitoshi Kashiwagi; Yuki Sato; Takayuki Miyai; Mitsuru Sugawara; Yoh Takekuma
  Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 26, 11, 1224, 1228, Elsevier BV, Nov. 2020, [Peer-reviewed], [International Magazine]
  English, Scientific journal, Cephalosporins with an N-methyl-thio-tetrazole (NMTT) side chain interact with warfarin by reducing the production of blood clotting factors. However, cephalosporins without the NMTT side chain also enhance the effects of warfarin. Thus, we aimed to compare the effects of warfarin modified by cephalosporins with and without the NMTT side chain, using a Japanese health insurance claims database. The inclusion criteria were patients who (1) intravenously received second- or third-generation cephalosporins between April 2010 and March 2017 and (2) received warfarin during cephalosporin therapy. Patients were administered either cephalosporins with the NMTT side chain (NMTT group) or those without NMTT (non-NMTT group). After matching patient data by propensity score, the following outcomes were compared between the two groups: (1) proportion of patients administered vitamin K, (2) proportion of bleeding events, and (3) changes in the daily dose of warfarin. Among 203 patients, 100 patients (50 per group) were matched by the propensity score. The proportion of patients administered vitamin K was 6.0% in both groups. These patients intravenously received a single dose of menatetrenone; no bleeding was observed. The proportion of patients subjected to a reduction in the daily dose of warfarin was 6.5% and 4.3% in the NMTT and non-NMTT groups, respectively. As our study had a small sample size, we could not determine whether the risk of over anticoagulation of warfarin is affected by cephalosporins with or without NMTT side chain. However, we showed the bleeding risk was sufficiently low regardless of the presence/absence of the NMTT side chain.
• Association of Initial Trough Concentrations of Vancomycin with Outcomes in Pediatric Patients with Gram-Positive Bacterial Infection.
  Miko Kondo; Shunsaku Nakagawa; Satoru Orii; Kotaro Itohara; Mitsuhiro Sugimoto; Tomohiro Omura; Yuki Sato; Satoshi Imai; Atsushi Yonezawa; Takayuki Nakagawa; Kazuo Matsubara
  Biological & pharmaceutical bulletin, 43, 10, 1463, 1468, Oct. 2020, [Peer-reviewed], [Domestic magazines]
  English, Scientific journal, Vancomycin is a glycopeptide antibiotic used for the treatment of Gram-positive infections. For adult patients, treatment with vancomycin requires effective therapeutic drug-monitoring (TDM) to achieve clinical outcomes and reduce the incidence of adverse effects. However, it remains still unclear whether the TDM with vancomycin is beneficial in yielding better clinical outcomes in pediatrics. The objective of our study was to evaluate whether the clinical response to treatment was associated with initial trough concentrations of vancomycin in pediatric patients. A retrospective observation study of 60 patients (age: 1 month-15 years) who had completed and qualified for analysis was conducted at Kyoto University Hospital. The response to treatment was assessed by the time to resolution of fever and time to 50% decline in C-reactive protein (CRP). In addition, we explored whether vancomycin trough level was associated with the baseline characteristics. Trend analysis showed that there were significant correlations between vancomycin trough level and age, body weight, estimated glomerular filtration rate, and serum albumin levels. The time to resolution of fever of the patients with higher initial trough level (≥ 5 µg/mL) was significantly lower than that of the patients with lower trough level (< 5 µg/mL). The higher vancomycin concentration tended to be associated with the shorter time to 50% decline in CRP. The findings suggest that initial trough concentration is important in achieving better outcomes with vancomycin treatment in pediatrics.
• Transfer of orally administered hyaluronan to the lymph.
  Yuki Sato; Tatsuru Joumura; Yoh Takekuma; Mitsuru Sugawara
  European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 154, 210, 213, Sep. 2020, [Peer-reviewed], [Lead author], [International Magazine]
  English, Scientific journal, Hyaluronan (HA) has been widely used in medicines, cosmetics and supplements for health and beauty maintenance. Oral administration is the most desirable and convenient means for consumers. The intestine plays an important role in immune system. We hypothesized that orally administered HA would be transferred to both blood and lymph. In this study, we investigated how orally administered HA was absorbed from the gastrointestinal tract and how much HA was incorporated. Four HA formulations, HA-2,000, 8,000, 50,000 and 300,000, were administered to rats, and concentrations of HA in blood and lymph were determined. In the HA-2,000 group, the HA plasma concentration increased after oral administration. The highest lymph concentration of HA was also obtained by administration of HA-2,000. The plasma and lymph concentrations slightly increased after oral administration in the HA-8,000 group. On the other hand, little absorption was found in the HA-50,000 and 300,000 groups. It is speculated that smaller molecules of HA are more easily absorbed. HA-2,000 was absorbed mainly through the portal vein and through the lymph in gastrointestinal absorption. This is the first report showing that HAs, large molecular weight and water-soluble molecules, after oral administration are transferred not only into blood but also into lymph.
• 2012-2018年における病棟薬剤師業務の質的変化 リファンピシン処方に対する介入を指標として
  吉田 優子; 佐藤 夕紀; 傳田 将也; 池見 泰明; 杉本 充弘; 山際 岳朗; 中川 俊作; 今井 哲司; 大村 友博; 尾崎 淳子; 深津 祥央; 矢野 育子; 北田 徳昭; 米澤 淳; 中川 貴之; 松原 和夫
  日本病院薬剤師会雑誌, 56, 6, 643, 650, (一社)日本病院薬剤師会, Jun. 2020, [Peer-reviewed]
  Japanese, Scientific journal
• Enhancement of intestinal absorption of coenzyme Q10 using emulsions containing oleyl polyethylene acetic acids.
  Yuki Sato; Sayaka Yokoyama; Yoshiaki Yamaki; Yuta Nishimura; Mami Miyashita; Shingo Maruyama; Yoh Takekuma; Mitsuru Sugawara
  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 142, 105144, 15 Jan. 2020, [Peer-reviewed], [Lead author], [International Magazine]
  English, Scientific journal, Emulsions have often been prepared to improve absorption of lipophilic compounds that have poor solubility. Coenzyme Q10 (CoQ10) is a lipophilic compound that has been used as an anti-aging supplement. We focused on oleyl polyethyleneoxy acetic acid, an oxa acid derivative, to prepare emulsions of CoQ10 with the expectation of application to oral pharmaceutics. Oxa acids were purified and classified into four groups based on the average length of the ethylene oxide chain. The emulsion that were prepared using the four oxa acid groups were administered to rats and the plasma concentration profiles of CoQ10 were analyzed. The absorption of CoQ10 was improved in all emulsion groups compared with that in the powder group. The emulsion using oxa acid (n = 9.0) greatly increased the plasma concentration of CoQ10. Absorption was also improved by using emulsions containing larger percentage of oxa acids (6%, 15% and 23%) to compared with the same oxa acid (n = 9.0). The effects of oxa acids on cell viability were almost the same as those of conventional surfactants such as polyoxyethylene (20) sorbitan monooleate (Tween 80). The results showed that oxa acids are useful to prepare emulsions for oral administration and that the absorption of CoQ10 using oxa acids is significantly improved by using our formulations.
• Higher incidence of acute kidney injury in patients treated with piperacillin/tazobactam than in patients treated with cefepime: a single-center retrospective cohort study.
  Shota Kadomura; Yoh Takekuma; Yuki Sato; Masato Sumi; Kotaro Kawamoto; Tatsuya Itoh; Mitsuru Sugawara
  Journal of pharmaceutical health care and sciences, 5, 13, 13, Jun. 2019, [Peer-reviewed], [International Magazine]
  English, Scientific journal, Background: Piperacillin/tazobactam (PIPC/TAZ) and cefepime (CFPM) are commonly used for the treatment of nosocomial and healthcare-associated infections. Recent reports have suggested that the incidence of acute kidney injury (AKI) in patients treated with a combination of vancomycin (VCM) and PIPC/TAZ is higher than that in patients treated with CFPM. However, there have been few reports on a comparison of the incidences of AKI in patients treated with PIPC/TAZ monotherapy and patients treated with CFPM. In this study, we investigated whether the incidence of AKI in patients treated with PIPC/TAZ is higher than that in patients treated with CFPM. Methods: This study was a single-center retrospective observational study. Patients who died during the therapeutic period, patients younger than 18 years of age, and patients undergoing hemodialysis were excluded. Primary outcomes were the incidence of AKI and the AKIN stages defined by the Acute Kidney Injury Network. Secondary outcomes were discontinuation and/or change of antibiotics and initiation of dialysis due to AKI. We also investigated the time to onset and the risk factors of AKI in this population. Results: There were 163 patients in the PIPC/TAZ group and 103 patients in the CFPM group. The incidence of AKI in patients treated with PIPC/TAZ (8.6%) was significantly higher than that in patients treated with CFPM (0.9%) (odds ratio (OR), 9.53; 95% confidence interval (CI), 1.41-408; p= 0.011). AKI severity was mostly stage 1 in both groups. There was no discontinuation and/or changes of antibiotics and there was no initiation of dialysis in either group. The onset of AKI in the PIPC/TAZ group (median period of 4 days) was earlier than that in the CFPM group. PIPC/TAZ was determined to be an independent risk factor of AKI in multivariate analysis (adjusted OR, 9.56; 95% CI, 1.21-75.3; p = 0.032). Conclusions: This study showed that the incidence of AKI in patients who received PIPC/TAZ was higher than that in patients who received CFPM. Furthermore, the onset of AKI was earlier in patients who received PIPC/TAZ than in patients who received CFPM. PIPC/TAZ was an independent risk factor of AKI in this study population.
• 学校薬剤師として実施した薬物乱用防止に関する授業の工夫例
  佐藤夕紀
  道学薬, 15, 35, 37, May 2019, [Invited], [Lead author, Corresponding author]
  Japanese, Symposium
• Concentration and Glycoform of Rituximab in Plasma of Patients with B Cell Non-Hodgkin's Lymphoma.
  Atushi Yonezawa; Yuki Otani; Toshiyuki Kitano; Mayuko Mori; Sho Masui; Yui Isomoto; Masahiro Tsuda; Satoshi Imai; Yasuaki Ikemi; Masaya Denda; Yuki Sato; Shunsaku Nakagawa; Tomohiro Omura; Takayuki Nakagawa; Ikuko Yano; Makoto Hayakari; Akifumi Takaori-Kondo; Kazuo Matsubara
  Pharmaceutical research, 36, 6, 82, 82, 15 Apr. 2019, [Peer-reviewed], [International Magazine]
  English, Scientific journal
• Effects of fasting on warfarin sensitivity index in patients undergoing cardiovascular surgery.
  Yoshiki Katada; Shunsaku Nakagawa; Akiko Nishimura; Yu-Ki Sato; Hiromi Taue; Katsuyuki Matsumura; Kazuhiro Yamazaki; Kenji Minakata; Ikuko Yano; Tomohiro Omura; Satoshi Imai; Atsushi Yonezawa; Yuki Sato; Takayuki Nakagawa; Kenji Minatoya; Kazuo Matsubara
  European journal of clinical pharmacology, 75, 4, 561, 568, Apr. 2019, [Peer-reviewed], [International Magazine]
  English, Scientific journal, PURPOSE: Warfarin shows large inter- and intra-individual variabilities in its pharmacokinetics and pharmacodynamics. Sufficient understanding of factors affecting the response to warfarin is necessary to achieve improved outcomes for warfarin therapy. In this study, we evaluated effects of fasting on the anticoagulant properties of warfarin. METHODS: We conducted a retrospective observational study involving a total of 58 patients, who received cardiovascular surgeries and subsequent warfarin therapy. The effect of dietary intake on the anticoagulant properties with warfarin was assessed by measurement of the international normalized ratio of prothrombin time (PT-INR): the anticoagulant activities of warfarin were expressed as the warfarin sensitivity index (WSI). Additionally, fluctuations in WSI during the study period were obtained as differences between the maximum and minimum WSI. RESULTS: The maximum PT-INR and WSI values were significantly higher for patients who were fasting for different reasons during the postoperative period than those in the group without reduced dietary intake. The differences between maximum and minimum WSI in the fasting group significantly increased compared with those in the groups with moderate or no reduced dietary intake. Meanwhile, effects of other markers of clinical conditions including the baseline Child-Pugh score and Charlson Comorbidity Index on WSI were not significant. CONCLUSIONS: Our results indicate that postoperative fasting was significantly associated with the anticoagulation activity of warfarin. In patients fasting for different reasons during the postoperative period, closer control of PT-INR values and warfarin adjustments may be required to avoid adverse effects such as bleeding in warfarin treatment.
• [Study of Formulation Development Based on the Pharmacokinetic Properties of Functional Food Components].
  Yuki Sato
  Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 139, 3, 341, 347, Mar. 2019, [Peer-reviewed], [Invited], [Lead author, Corresponding author], [Domestic magazines]
  Japanese, Scientific journal, Preventive medicine and anti-aging medicine have received much attention recently due to an increase in the proportion of elderly people in the population, and to an increase in patients with lifestyle diseases. Oxidative stress is involved in the onset of lifestyle diseases, and various antioxidant supplements and antioxidant-fortified functional foods have recently become available. Many epidemiological studies have shown relationships between the consumption of polyphenol and carotenoid-rich foods and the prevention of lifestyle diseases. We have focused on the absorption mechanism of these food components that show low bioavailability, and have made efforts to improve their poor absorption based on their pharmacokinetic properties. In this report, as examples, we describe the enhancement of the absorption of coenzyme Q10 (CoQ10) and lutein. To improve the absorption of CoQ10, we focused on the component of emulsion. We found that a higher plasma concentration of CoQ10 could be obtained by creating an emulsion containing a surfactant with a higher hydrophile-lipophile balance (HLB) value. For the improvement of lutein absorption, we prepared a solid dispersion and self-emulsifying drug delivery system. It was shown that the plasma concentrations of lutein in these two formulation groups were increased compared with that in the powder group. The absorption of lutein was also evaluated by its cumulative amount in the lymph system. Our data showed that lutein is transferred from the small intestine into the lymph stream, rather than into the blood stream. Further investigations to improve the absorption of these components are in progress.
• [Analysis by Using Roter Method of Interaction Process Analysis (RIAS) of the Ability of Pharmacy Students to Communicate after Clinical Training for Pharmacy].
  Yoh Takekuma; Ayako Mori; Masaki Kobayashi; Yuma Yamada; Yuki Sato; Katsuya Narumi; Ayako Furugen; Mitsuru Sugawara
  Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 138, 12, 1579, 1586, (公社)日本薬学会, Dec. 2018, [Peer-reviewed], [Domestic magazines]
  Japanese, Scientific journal, Communication education is now necessary for pharmaceutical education since the role of pharmacists has expanded from "medicine-based" to "person-based". However, a standard for assessing the effectiveness of a communication education program has not been established. Hence, the aim of this study was to determine the effectiveness of clinical training in pharmacy for enhancing the ability of pharmacy students to communicate. Role playing with simulated patients was performed by pharmacy students before and after clinical practice for pharmacy, and the effects of learning were analyzed by Roter method of interaction process analysis (RIAS). Analysis by RIAS enabled quantification and objective evaluation of communication by pharmacy students. The results showed improvement of interactive communication, decrease of "Question asking" and "Others" including "Transition words", and increase of "Partnership behaviors" and "Counsel behaviors". The pharmacy students became skillful in communication without showing hesitation. The results therefore showed that clinical training contributes to improvement in the ability of pharmacy students to communicate.
• Analysis of Glycoforms and Amino Acids in Infliximab and a Biosimilar Product Using New Method with LC/TOF-MS.
  Masahiro Tsuda; Yuki Otani; Atsushi Yonezawa; Sho Masui; Yasuaki Ikemi; Masaya Denda; Yuki Sato; Shunsaku Nakagawa; Tomohiro Omura; Satoshi Imai; Takayuki Nakagawa; Makoto Hayakari; Kazuo Matsubara
  Biological & pharmaceutical bulletin, 41, 11, 1716, 1721, 01 Nov. 2018, [Peer-reviewed], [Domestic magazines]
  English, Scientific journal, Biosimilar products of therapeutic antibodies have been launched all over the world. They can relieve some of the economic burden of medicines. Although clinical trials have demonstrated the equivalency of biosimilar products with their reference product, biosimilar products are not commonly used in clinical practice. One reason is that the structural difference between the reference product and a biosimilar one remains unclear. We analyzed glycoforms and amino acids of an infliximab biosimilar product approved in Japan compared to that of the reference product (Remicade®). By combination of papain digestion and LC/ time-of-flight (TOF)-MS, we established a valuable method to analyze these therapeutic antibodies. Nine glycoforms were detected in infliximab, and a difference in amino acids was observed. In the glycoforms of MMF, MGnF/GnMF, GnGn, GnGnF, AGnF/GnAF, and AAF, the relative intensities were significantly different between the reference and biosimilar product. Furthermore, we elucidated that the content rate of the C-terminal lysine was different among glycoforms. In conclusion, our analytical method can analyze not only amino acids but also carbohydrate chains of therapeutic antibodies, and will provide a useful strategy to evaluate bio-medicines including biosimilar antibodies.
• Oxicam-derived non-steroidal anti-inflammatory drugs suppress 1-methyl-4-phenyl pyridinium-induced cell death via repression of endoplasmic reticulum stress response and mitochondrial dysfunction in SH-SY5Y cells.
  Tomohiro Omura; Miwa Sasaoka; Gaia Hashimoto; Satoshi Imai; Joe Yamamoto; Yuki Sato; Shunsaku Nakagawa; Atsushi Yonezawa; Takayuki Nakagawa; Ikuko Yano; Yoshikazu Tasaki; Kazuo Matsubara
  Biochemical and biophysical research communications, 503, 4, 2963, 2969, 18 Sep. 2018, [Peer-reviewed], [International Magazine]
  English, Scientific journal, We have previously reported that oxicam-derived non-steroidal anti-inflammatory drugs (oxicam-NSAIDs), including meloxicam, piroxicam and tenoxicam, elicit protective effects against 1-methyl-4-phenyl pyridinium (MPP+)-induced cell death in a fashion independent of cyclooxygenase (COX) inhibition. We have also demonstrated that oxicam-NSAIDs suppress the decrease in phosphorylation of Akt caused by MPP+. The molecular mechanism through which oxicam-NSAIDs provide cytoprotection remains unclear. In this study, we speculated a possibility that endoplasmic reticulum (ER) stress and/or mitochondrial dysfunction, which are both causative factors of Parkinson's disease (PD), may be involved in the neuroprotective mechanism of oxicam-NSAIDs. We demonstrated here that oxicam-NSAIDs suppressed the activation of caspase-3 and cell death caused by MPP+ or ER stress-inducer, tunicamycin, in SH-SY5Y cells. Furthermore, oxicam-NSAIDs suppressed the increases in the ER stress marker CHOP (apoptosis mediator) caused by MPP+ or tunicamycin, beside suppressing eukaryotic initiation factor 2α (eIF2α) phosphorylation and the increase in ATF4 caused by MPP+. Taken together, these results suggest that oxicam-NSAIDs suppress the eIF2α-ATF4-CHOP pathway, one of the three signaling pathways in the ER stress response. Oxicam-NSAIDs suppressed the decrease in mitochondrial membrane potential depolarization caused by MPP+, indicating they also rescue cells from mitochondrial dysfunction. Akt phosphorylation levels were suppressed after the incubation with MPP+, whereas phosphorylation of eIF2α was enhanced. These results suggest that oxicam-NSAIDs prevented eIF2α phosphorylation and mitochondrial dysfunction by maintaining Akt phosphorylation (reduced by MPP+), thereby preventing cell death.
• Enhancement of lymphatic transport of lutein by oral administration of a solid dispersion and a self-microemulsifying drug delivery system.
  Yuki Sato; Tatsuru Joumura; Shunsuke Nashimoto; Sayaka Yokoyama; Yoh Takekuma; Hideto Yoshida; Mitsuru Sugawara
  European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 127, 171, 176, Jun. 2018, [Peer-reviewed], [Lead author], [International Magazine]
  English, Scientific journal, Lutein is located in the macula lutea in the human eye. Since humans cannot synthesize lutein de novo, it must be digested as food. Some studies including our previous study showed very low absorption of lutein after oral administration. These studies also suggested that the absorption route of lutein from the small intestine involves not only the blood but also the lymph. The aim of this study was to clarify the transfer of lutein into lymph and the tissue distribution after oral administration of a solid dispersion (SD) and a self-microemulsifying drug delivery system (SMEDDS) for improvement of the absorption. We used thoracic lymph-cannulated rats. It was shown that the plasma concentrations of lutein in the SD and SMEDDS groups were increased compared with that in the powder group. The absorption of lutein after oral administration of each formulation was clearly evaluated by its cumulative amount in lymph. Our data clearly showed that lutein is transferred into the lymph stream from the small intestine.
• 機能性食品成分ルテインの製剤化による吸収改善
  佐藤夕紀
  アグリバイオ, 2, 4, 411‐413, Apr. 2018, [Invited]
  Japanese
• 小学校の授業を通して見えてきたことと今後の課題
  佐藤夕紀; 宮下元樹; 菅原満
  道学薬, 13, 37, 40, May 2017, [Invited], [Lead author, Corresponding author]
  Japanese, Symposium
• Inhibitory effect of ezetimibe can be prevented by an administration interval of 4 h between alpha-tocopherol and ezetimibe
  Shunsuke Nashimoto; Yuki Sato; Yoh Takekuma; Mitsuru Sugawara
  BIOPHARMACEUTICS & DRUG DISPOSITION, 38, 4, 280, 289, May 2017, [Peer-reviewed], [Lead author]
  English, Scientific journal
• 低吸収性機能性食品成分の吸収特性を考慮した消化管吸収改善のための製剤開発
  佐藤夕紀
  アグリバイオ, 1, 4, 495‐498, Apr. 2017, [Invited]
  Japanese
• Difference in the Dissolution Behaviors of Tablets Containing Polyvinylpolypyrrolidone (PVPP) Depending on Pharmaceutical Formulation After Storage Under High Temperature and Humid Conditions
  Yoh Takekuma; Haruka Ishizaka; Masato Sumi; Yuki Sato; Mitsuru Sugawara
  JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES, 19, 4, 511, 519, Apr. 2016, [Peer-reviewed]
  English, Scientific journal

  
  Download
• An Approach to Improve Intestinal Absorption of Poorly Absorbed Water-Insoluble Components via Niemann Pick C1-Like 1
  Yuto Takekawa; Yuki Sato; Yoshiaki Yamaki; Mei Imai; Kazuma Noto; Masato Sumi; Yoh Takekuma; Ken Iseki; Mitsuru Sugawara
  BIOLOGICAL & PHARMACEUTICAL BULLETIN, 39, 3, 301, 307, Mar. 2016, [Peer-reviewed]
  English, Scientific journal
• 開封後のスタチン製剤の安定性に及ぼす光・温度・湿度の影響
  武隈 洋; 高地 里佳; 石坂 悠; 佐藤 夕紀; 鷲見 正人; 菅原 満
  医療薬学, 40, 3, 135, 146, (一社)日本医療薬学会, Mar. 2014, [Peer-reviewed]
  Japanese, Scientific journal, 開封後のスタチン製剤の安定性に及ぼす光・温度・湿度の影響について検討した。安定性評価の対象とした薬剤は、ロスバスタチン製剤1銘柄2規格、シンバスタチン製剤4銘柄、プラバスタチン製剤4銘柄である。安定性評価の対象薬剤を、一包化した状態を想定してPTPシートから出し、薬包紙を用いて1錠ずつ包んだ。また、散光条件下のみセロポリ分包紙を用いて1錠ずつ分包した。ロスバスタチン製剤はPTPから開封しても室温散光条件下で1年間安定で、一包化調剤後でも患者が通常家庭内で保存する分には大きな問題は生じないことが示唆されたが、粉砕調剤時には遮光保存が必須条件であることが示された。シンバスタチン製剤は、6ヵ月間保存した場合、すべての条件下で安定であったのは1製剤のみであった。プラバスタチン製剤は、すべての製剤において室温遮光条件下で6ヵ月間安定であることが示されたが、散光条件下では一部の製剤に変色が確認された。
• Emulsification Using Highly Hydrophilic Surfactants Improves the Absorption of Orally Administered Coenzyme Q10
  Yuki Sato; Hanami Mutoh; Mika Suzuki; Yoh Takekuma; Ken Iseki; Mitsuru Sugawara
  BIOLOGICAL & PHARMACEUTICAL BULLETIN, 36, 12, 2012, 2017, Dec. 2013, [Peer-reviewed], [Lead author]
  English, Scientific journal
• Intracellular Uptake Mechanism of Lutein in Retinal Pigment Epithelial Cells
  Yuki Sato; Yu Kondo; Masato Sumi; Yoh Takekuma; Mitsuru Sugawara
  JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES, 16, 3, 494, 501, Jul. 2013, [Peer-reviewed], [Lead author]
  English, Scientific journal
• Involvement of Cholesterol Membrane Transporter Niemann-Pick C1-Like 1 in the Intestinal Absorption of Lutein
  Yuki Sato; Risa Suzuki; Masaki Kobayashi; Shirou Itagaki; Takeshi Hirano; Toshihiro Noda; Satoshi Mizuno; Mitsuru Sugawara; Ken Iseki
  JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES, 15, 2, 256, 264, Apr. 2012, [Peer-reviewed], [Lead author]
  English, Scientific journal

  
  Download
• Protective Effect of Soy Isoflavone Genistein on Ischemia-Reperfusion in the Rat Small Intestine
  Yuki Sato; Shirou Itagaki; Setsu Oikawa; Jiro Ogura; Masaki Kobayashi; Takeshi Hirano; Mitsuru Sugawara; Ken Iseki
  BIOLOGICAL & PHARMACEUTICAL BULLETIN, 34, 9, 1448, 1454, Sep. 2011, [Peer-reviewed], [Lead author]
  English, Scientific journal
• Protective effect of lutein after ischemia-reperfusion in the small intestine
  Yuki Sato; Masaki Kobayashi; Shirou Itagaki; Takeshi Hirano; Toshihiro Noda; Satoshi Mizuno; Mitsuru Sugawara; Ken Iseki
  FOOD CHEMISTRY, 127, 3, 893, 898, Aug. 2011, [Peer-reviewed], [Lead author]
  English, Scientific journal
• Pharmacokinetic properties of lutein emulsion after oral administration to rats and effect of food intake on plasma concentration of lutein
  Yuki Sato; Masaki Kobayashi; Shirou Itagaki; Takeshi Hirano; Toshihiro Noda; Satoshi Mizuno; Mitsuru Sugawara; Ken Iseki
  BIOPHARMACEUTICS & DRUG DISPOSITION, 32, 3, 151, 158, Apr. 2011, [Peer-reviewed], [Lead author]
  English, Scientific journal
• In vitro and in vivo antioxidant properties of chlorogenic acid and caffeic acid
  Yuki Sato; Shirou Itagaki; Toshimitsu Kurokawa; Jiro Ogura; Masaki Kobayashi; Takeshi Hirano; Mitsuru Sugawara; Ken Iseki
  INTERNATIONAL JOURNAL OF PHARMACEUTICS, 403, 1-2, 136, 138, Jan. 2011, [Peer-reviewed], [Lead author]
  English, Scientific journal
• Characterization of the disposition of lutein after i.v. administration to rats
  Shirou Itagaki; Wakako Ogura; Yuki Sato; Toshihiro Noda; Takeshi Hirano; Satoshi Mizuno; Ken Iseki
  BIOLOGICAL & PHARMACEUTICAL BULLETIN, 29, 10, 2123, 2125, Oct. 2006, [Peer-reviewed]
  English, Scientific journal

• 重症高齢患者における腎過剰ろ過の発生率,推定,危険因子,経時的変化に関する検討
  三上龍生; 三上龍生; 今井俊吾; 早川峰司; 泉岳; 柏木仁; 佐藤夕紀; 梨本俊亮; 和田剛志; 菅原満; 菅原満; 武隈洋, 日本集中治療医学会学術集会(Web), 53rd, 2026
• Investigation of the mechanism underlying reduced plasma concentration of mycophenolic acid during co-administration of the cardiovascular drug sacubitril/valsartan
  梨本俊亮; 尾上尚吾; 佐藤夕紀; 柏木仁; 武隈洋; 菅原満; 菅原満, 日本薬学会年会要旨集(Web), 146th, 2026
• 未分画ヘパリンモニタリングにおけるAPTTと抗Xa活性の不一致に対する腎機能の影響 探索的後ろ向き観察研究
  三上 龍生; 早川 峰司; 今井 俊吾; 斉藤 智誉; 佐藤 夕紀; 柏木 仁; 梨本 俊亮; 菅原 満; 武隈 洋, 日本腎臓病薬物療法学会誌, 14, 特別号, S172, S172, Sep. 2025
  (一社)日本腎臓病薬物療法学会, Japanese
• 未分画ヘパリンモニタリングにおけるAPTTと抗Xa活性の不一致に対する腎機能の影響 探索的後ろ向き観察研究
  三上 龍生; 早川 峰司; 今井 俊吾; 斉藤 智誉; 佐藤 夕紀; 柏木 仁; 梨本 俊亮; 菅原 満; 武隈 洋, 日本腎臓病薬物療法学会誌, 14, 特別号, S172, S172, Sep. 2025
  (一社)日本腎臓病薬物療法学会, Japanese
• 非小細胞肺がん患者におけるドセタキセル誘発性浮腫の要因分析
  山下 慎介; 齋藤 佳敬; 今井 俊吾; 柏木 仁; 佐藤 夕紀; 梨本 俊亮; 榊原 純; 清水 康; 木下 一郎; 武隈 洋; 菅原 満, 日本臨床腫瘍薬学会雑誌, 41, 139, 139, May 2025
  (一社)日本臨床腫瘍薬学会, Japanese
• Substrate-modified liposome uptake by endocytosis via amino acid transporter SNAT4
  松山琳空; 佐藤夕紀; 藤田聡; 丸山真吾; 梨本俊亮; 柏木仁; 武隈洋; 菅原満; 菅原満, 日本薬剤学会年会講演要旨集(CD-ROM), 40年会, 130, 130, May 2025
  (公社)日本薬剤学会, Japanese
• リネゾリド投与による嘔気嘔吐発現メカニズムの探索~セロトニン産生腫瘍細胞株QGP-1を用いた検討~
  堤竹蔵; 堤竹蔵; 柏木仁; 佐藤夕紀; 今井俊吾; 梨本俊亮; 菅原満; 菅原満; 武隈洋, 医療薬学フォーラム講演要旨集, 33rd, 2025
• Establishment of a monolayer culture system for jejunal epithelial cells that allows evaluation of transport activity
  笹川義樹; 神嶋莉穂; 柏木仁; 佐藤夕紀; 梨本俊亮; 武隈洋; 菅原満; 菅原満, 日本薬学会年会要旨集(Web), 145th, 2025
• Evaluation of whether middle molecules are substrates for P-gp using P-gp-overexpressing cells
  柏木仁; 山田隼大; 王子谷健太; 佐藤夕紀; 梨本俊亮; 渡邉瑞貴; 廣瀬友靖; 廣瀬友靖; 岩月正人; 岩月正人; 砂塚敏明; 砂塚敏明; 金光佳世子; 石井真由美; 渡邊恵里; 宮地弘幸; 武隈洋; 菅原満; 菅原満, 日本薬学会年会要旨集(Web), 145th, 2025
• Regulation of the activity of amino acid transporter SNAT4 by platelets
  柏木仁; 佐藤夕紀; 梨本俊亮; 今井俊吾; 武隈洋; 菅原満; 菅原満, 日本薬学会年会要旨集(Web), 145th, 2025
• Development and validation of the prediction score for augmented renal clearance in Japanese intensive care units
  三上龍生; 三上龍生; 今井俊吾; 早川峰司; 佐藤夕紀; 柏木仁; 梨本俊亮; 菅原満; 武隈洋, 日本薬学会年会要旨集(Web), 145th, 2025
• Exploring the impact of baseline platelet count on linezolid-induced thrombocytopenia: a retrospective single-center observation study.
  Yuki Inoue; Hitoshi Kashiwagi; Yuki Sato; Shunsuke Nashimoto; Mitsuru Sugawara; Yoh Takekuma, International journal of clinical pharmacy, 145th, 04 Oct. 2024, [Peer-reviewed], [International Magazine]
  BACKGROUND: Patients treated with linezolid (LZD) frequently develop thrombocytopenia, and previous studies have identified the risk factors for this condition. However, the relationship between the development of LZD-induced thrombocytopenia and baseline platelet count has varied according to different reports. AIM: To explore the relationship between platelet count and the development of LZD-induced thrombocytopenia. METHOD: Patients who underwent LZD at Hokkaido University Hospital in Japan from September 2008 to March 2023 were included. We collected data on patient characteristics and platelet counts at baseline and during LZD therapy from the electronic medical records. Thrombocytopenia was defined as a decrease in platelet count by 30% or more from baseline, or a platelet level < 100,000/µL. RESULTS: Two hundred and ninety-five patients who received LZD were included in this study, of whom 34.9% developed thrombocytopenia. In the early days of LZD treatment, the thrombocytopenia group showed a nearly 5% decrease in platelet count, while the non-thrombocytopenia group exhibited an increase of over 5%. Additionally, focusing on early onset thrombocytopenia (within 5 days), a baseline platelet count of < 150,000/µL was identified as a risk factor for early thrombocytopenia. Conversely, it was also observed that 24.7% of patients with a baseline platelet count ≥ 150,000/µL still developed early thrombocytopenia. CONCLUSION: Our findings suggest that while a baseline platelet count of < 150,000/µL is a risk factor for the early onset of thrombocytopenia, vigilant monitoring of platelet counts by clinical pharmacists in the early stages of LZD treatment is essential, regardless of baseline platelet levels., English
• 医療薬科学 HDL-コレステロール値は高くても低くても認知症発症リスクと関連する
  佐藤 夕紀, ファルマシア, 60, 8, 799, 799, Aug. 2024
  (公社)日本薬学会, Japanese
• 医療薬科学 HDL-コレステロール値は高くても低くても認知症発症リスクと関連する
  佐藤 夕紀, ファルマシア, 60, 8, 799, 799, Aug. 2024
  (公社)日本薬学会, Japanese
• ヒアルロン酸4,6,8糖の同時定量法の確立
  佐藤 夕紀; 高林 直央; 青柳 空馬; 梨本 俊亮; 柏木 仁; 武隈 洋; 菅原 満, 日本薬剤学会年会講演要旨集, 39年会, 201, 201, May 2024
  (公社)日本薬剤学会, Japanese
• マスメディアによる「くすりの危険性」に関する報道に起因した患者相談の実態調査
  今井 俊吾; 阿部 真也; 松井 洸; 柏木 仁; 佐藤 夕紀; 武隈 洋; 吉町 昌子; 菅原 満, 日本医薬品情報学会総会・学術大会講演要旨集, 25回, 132, 132, Jun. 2023
  (一社)日本医薬品情報学会, Japanese
• Evaluation of absorption and properties of emulsion and self-emulsifying drug delivery system of cyclosporine A
  佐藤夕紀; 木下祐介; 上村聡; 丸山真吾; 武隈洋; 菅原満; 菅原満, 日本薬剤学会年会講演要旨集(CD-ROM), 38年会, 171, 171, May 2023
  (公社)日本薬剤学会, Japanese
• 牛乳成分を用いた乳剤化によるコエンザイムQ10の吸収改善効果
  山内佑紀恵; 八巻義朗; 佐藤夕紀; 柏木仁; 梨本俊亮; 武隈洋; 菅原満; 菅原満, 日本医療薬学会年会講演要旨集(Web), 33rd, 2023
• Development of a method of simultaneous determination of orally administered hyaluronan oligosaccharides
  高林直央; 佐藤夕紀; 柏木仁; 梨本俊亮; 武隈洋; 菅原満; 菅原満, バイオメディカル分析科学シンポジウム講演要旨集, 35th, 2023
  Japanese, Summary national conference
• Risk Factor Analysis of Vancomycin-Induced Nephrotoxicity in Paediatric Patients Aged 0-1 Year Using Japanese Medical Database.
  Takayuki Miyai; Yoh Takekuma; Hitoshi Kashiwagi; Yuki Sato; Shunsuke Nashimoto; Mitsuru Sugawara; Shungo Imai, Biological & pharmaceutical bulletin, 46, 6, 817, 823, 2023, [Peer-reviewed], [Domestic magazines]
  Vancomycin (VCM)-induced nephrotoxicity (VIN) is a major side effect in paediatric patients. However, most studies are limited to patients aged 0-18 years. We evaluated the risk factors of VIN in patients aged 0-1 year using Japanese electronic medical record database. We used RWD database which was contained electronic medical records and claims data of approximately 20 million people from 160 medical institutions. We targeted hospitalized patients who were administered VCM between June 2000 and December 2020. VIN was defined by two criteria: Criterion 1 was an increase in serum creatinine (Scr) ≥ 0.5 mg/dL or 50% during VCM treatment period compared to the Scr baseline; and criterion 2 was an increase in Scr ≥50% within seven days or Scr ≥0.3 mg/dL within two days during VCM treatment. The risk factors of VIN were evaluated using multivariate logistic regression analysis. We analysed 446 patients; patients with VIN in Criteria 1 and 2 were 33 and 58, respectively. In Criterion 1, multivariate logistic regression analysis identified four independent factors with p-value <0.05 (VCM concentration ≥20 mg/L, amphotericin B (AMPH-B), piperacillin-tazobactam (TAZ/PIPC), and vasopressor drugs). In Criterion 2, multivariate logistic regression analysis identified concomitant use of vasopressor drugs with p-value <0.05. Therefore, concomitant use of vasopressor drugs was suggested to affect the risk of VIN in patients aged 0-1 year. The findings may help in developing estimation models to assess the risk of VIN in paediatric patients., English
• 週刊誌に掲載された「危ないクスリ」に関する情報の整理とその適切性評価
  今井 俊吾; 柏木 仁; 佐藤 夕紀; 武隈 洋; 菅原 満, 日本医薬品情報学会総会・学術大会講演要旨集, 24回, 91, 91, Jun. 2022
  (一社)日本医薬品情報学会, Japanese
• 大規模レセプトデータベースを用いたボリコナゾールの治療薬物モニタリング実施に関する実態調査
  宮井 貴之; 今井 俊吾; 百 賢二; 柏木 仁; 佐藤 夕紀; 菅原 満; 武隈 洋, 日本薬学会年会要旨集, 142年会, 27G, am09S, Mar. 2022
  (公社)日本薬学会, Japanese
• Search for new etoposide derivatives overcoming multidrug resistance in cancer
  山田隼大; 王子谷健太; 柏木仁; 佐藤夕紀; 今井俊吾; 宮地弘幸; 武隈洋; 菅原満; 菅原満, 日本薬学会年会要旨集(Web), 142年会, 28C, pm04S, Mar. 2022
  (公社)日本薬学会, Japanese
• Use of Japanese big data and a data mining analysis to investigate risk factors for linezolid-induced thrombocytopenia
  井上優希; 武隈洋; 宮井貴之; 柏木仁; 佐藤夕紀; 菅原満; 菅原満; 今井俊吾, 日本薬学会年会要旨集(Web), 142年会, 28H, pm13S, Mar. 2022
  (公社)日本薬学会, Japanese, Meeting report
• レセプトデータベースを用いた糖尿病患者へのオランザピンの処方実態調査
  山下慎介; 山下慎介; 今井俊吾; 今井俊吾; 百賢二; 百賢二; 柏木仁; 佐藤夕紀; 菅原満; 菅原満; 武隈洋, 日本医療薬学会年会講演要旨集(Web), 32, 2022
• LC/MS/MSを用いたリネゾリドならびにテジゾリドのヒト血漿中濃度同時定量法の確立
  佐藤夕紀; 大聖貴之; 柏木仁; 今井俊吾; 武隈洋; 菅原満; 菅原満, 日本医療薬学会年会講演要旨集(Web), 32, 2022
• リネゾリド投与患者における嘔吐発現要因の探索
  堤竹蔵; 堤竹蔵; 今井俊吾; 今井俊吾; 柏木仁; 佐藤夕紀; 菅原満; 菅原満; 菅原満; 武隈洋, 日本医療薬学会年会講演要旨集(Web), 32, 2022
• Development an imaging method for increasing intestinal blood flow by ingredients contained in supplements
  佐藤夕紀, アグリバイオ, 5, 10, 899, 902, Sep. 2021, [Invited], [Lead author, Corresponding author]
  Japanese, Introduction commerce magazine
• 卵黄レシチンを用いた乳剤化に適した化合物の物理化学的特性
  鳥山 竜也; 佐藤 夕紀; 柏木 仁; 今井 俊吾; 武隈 洋; 菅原 満, 日本薬学会年会要旨集, 141年会, 28V11, pm06S, Mar. 2021
  (公社)日本薬学会, Japanese
• 吸収トランスポーターの機能解析へのエンテロイドの応用
  島田 美紀子; 佐藤 夕紀; 柏木 仁; 今井 俊吾; 武隈 洋; 菅原 満, 日本薬学会年会要旨集, 141年会, 29V07, am05S, Mar. 2021
  (公社)日本薬学会, Japanese
• オンライン会議システムを活用した医療面接実習の実践
  森 綾子; 加藤 いづみ; 柏木 仁; 今井 俊吾; 鳴海 克哉; 佐藤 夕紀; 古堅 彩子; 山田 勇磨; 小林 正紀, 日本薬学会年会要旨集, 141年会, 29V11, pm04, Mar. 2021
  (公社)日本薬学会, Japanese
• Intestinal absorption of orally administered hyaluronan
  佐藤夕紀, アグリバイオ, 4, 14, 1305, 1307, Dec. 2020, [Invited], [Corresponding author]
  Japanese, Introduction commerce magazine
• Enhancement of intestinal absorption of coenzyme Q10 using emulsions containing oleyl polyethylene acetic acids
  佐藤夕紀, アグリバイオ, 4, 8, 680, 682, Jul. 2020, [Invited], [Lead author, Corresponding author]
  Japanese, Introduction commerce magazine
• Inhibitory effect of Hangeshashinto oral ointment on 5-fluorouracil-induced oral mucositis model in Syrian hamsters
  荻原孝史; 香川雅登; 佐藤夕紀; 中川俊作; 米澤淳; 今井哲司; 伊藤美千穂; 中川貴之; 松原和夫, 日本薬学会年会要旨集(Web), 140年会, 27Y, am06S, Mar. 2020
  (公社)日本薬学会, Japanese
• Xenopus laevis oocyteを用いたコレステロールトランスポーターNiemann-Pick C1-Like1(NPC1L1)発現系の構築
  梨本俊亮; 八木沙織; 武田直樹; 野中美玖; 武隈洋; 菅原満; 菅原満; 佐藤夕紀, トランスポーター研究会年会抄録集, 15th, 2020
• クロザピン及び活性代謝物の母集団薬物動態解析：入院・外来の影響
  小岸かれん; 大村友博; 山本将太; 中川俊作; 米澤淳; 糸原光太郎; 竹内理人; 松尾研志; 橋本凱朝; 諏訪太朗; 佐藤夕紀; 今井哲司; 中川貴之; 村井俊哉; 矢野育子; 松原和夫, 日本医療薬学会年会講演要旨集(Web), 29, Nov. 2019, [Peer-reviewed]
  Japanese, Summary national conference
• トルリシティの有害事象による中止の臨床的要因の探索
  中川佳代子; 佐藤夕紀; 中川俊作; 吉田優子; 傳田将也; 木全柾典; 今井哲司; 米澤淳; 中川貴之; 稲垣暢也; 原田範雄; 小倉雅仁; 松原和夫, 日本医療薬学会年会講演要旨集(Web), 29, Nov. 2019, [Peer-reviewed]
  Japanese, Summary national conference
• 小児肝移植後患者におけるバンコマイシンのPPKモデリング＆シミュレーション
  折井悟; 中川俊作; 松尾研志; 杉本充弘; 糸原光太郎; 佐藤夕紀; 今井哲司; 米澤淳; 中川貴之; 松原和夫, 第13回次世代を担う若手医療薬科学シンポジウム, Oct. 2019, [Peer-reviewed]
  Japanese, Summary national conference
• コレステロールトランスポーターNPC1L1を介したコエンザイムQ10の消化管吸収
  梨本俊亮; 竹川悠人; 佐藤夕紀; 武隈洋; 菅原満, 第１４回トランスポーター研究会年会, Jul. 2019, [Peer-reviewed]
  Japanese, Summary national conference
• 低吸収性を示す機能性食品成分の消化管吸収機構の解明と吸収特性を考慮した製剤開発
  佐藤 夕紀, 薬学雑誌, 139, 3, 341, 347, Mar. 2019
  近年、悪性新生物、虚血性心疾患など活性酸素種が関与している疾病の予防、進行防止を目的とした抗酸化作用を持つ機能性食品やその成分を利用したサプリメント等が開発されている。筆者らは特に、低吸収性を示す機能性食品成分に着目し、その消化管吸収機構の解明とその吸収特性を考慮した製剤開発について検討してきた。これまで検討した成分の中から、コエンザイムQ10やルテインの消化管吸収改善について述べた。, (公社)日本薬学会, Japanese
• 門脈およびリンパ管への薬物移行を考慮した消化管吸収の評価
  定村 樹; 佐藤 夕紀; 武隈 洋; 菅原 満, 日本薬学会年会要旨集, 139年会, 4, 61, 61, Mar. 2019, [Peer-reviewed]
  (公社)日本薬学会, Japanese, Summary national conference
• 薬学実務実習前後における薬学生のコミュニケーション分析 RIAS(Roter method of interaction process analysis)を用いて
  武隈 洋; 森 綾子; 小林 正紀; 山田 勇磨; 佐藤 夕紀; 鳴海 克哉; 古堅 彩子; 菅原 満, 日本薬学会年会要旨集, 139年会, 4, 212, 212, Mar. 2019
  (公社)日本薬学会, Japanese
• 抗真菌薬に関する適正使用支援チームにおける薬剤師の役割
  木全柾典; 中川俊作; 片田佳希; 杉本充弘; 吉田優子; 糸原光太郎; 深津祥央; 佐藤夕紀; 今井哲司; 米澤淳; 米澤淳; 中川貴之; 松村康史; 長尾美紀; 松原和夫, 日本医療薬学会年会講演要旨集(Web), 29, 2019
• 機能性食品成分の吸収動態特性を踏まえた製剤学的アプローチ
  佐藤夕紀, 日本食品科学工学会大会講演集, 66th, 2019
• エンテロイドを用いた薬物排出トランスポーターの機能解析
  小関 千尋; 石川 岳彦; 佐藤 夕紀; 武隈 洋; 菅原 満, 日本薬学会年会要旨集, 139th, 4, 68, 68, 2019, [Peer-reviewed]
  (公社)日本薬学会, Japanese, Summary national conference
• Xenopus laevis oocytesを用いたNiemann-Pick C1-Like 1(NPC1L1)発現系の最適化
  八木 沙織; 梨本 俊亮; 佐藤 夕紀; 鷲見 正人; 武隈 洋; 菅原 満, 日本薬学会年会要旨集, 139th, 4, 68, 68, 2019
  (公社)日本薬学会, Japanese
• エンテロイドは薬物排出トランスポーターの機能解析ツールになり得るか
  小関千尋; 石川岳彦; 佐藤夕紀; 武隈 洋; 菅原 満, 第32回北海道薬物作用談話会, Jul. 2018
  Japanese, Summary national conference
• 消化管活動性がニロチニブの吸収性に及ぼす影響
  佐々木真彩; 青山剛; 佐藤夕紀; 武隈洋; 菅原満, 医療薬学フォーラム講演要旨集, 26th, 249, Jun. 2018
  Japanese
• オキサ酸を用いた乳剤化によるクルクミンの吸収改善と消化管への影響の評価
  西村悠汰; 八巻義朗; 佐藤夕紀; 武隈 洋; 丸山真吾; 菅原 満, 日本薬学会北海道支部第145 回例会, May 2018
  Japanese, Summary national conference
• 肝遊離細胞サンドイッチ培養法を用いたカルベジロールの輸送および代謝における光学異性体間相互作用の解析
  伊藤圭祐; 佐々木萌子; 佐藤夕紀; 鷲見正人; 武隈洋; 菅原満, 日本薬学会年会要旨集(CD-ROM), 138th, 4, ROMBUNNO.27C‐am03, 51, 2018
  (公社)日本薬学会, Japanese
• マクロファージに着目したHIV誘発末梢神経障害性疼痛の機序解明
  平岩怜; 今井哲司; NTOGWA Mpumelelo; 小柳円花; 佐藤夕紀; 中川俊作; 大村友博; 米澤淳; 中川貴之; 松原和夫, 鎮痛薬・オピオイドペプチドシンポジウムプログラム・抄録集, 38th, 43, 2018
  Japanese
• 小腸オルガノイドを利用した排出系トランスポータの基質関与探索ツールの構築
  佐藤夕紀; 中村公則; 小関千尋; 石川岳彦; 島田美紀子; 横井友樹; 本間直幸; 森山隆則; 菅原満, トランスポーター研究会年会抄録集, 13th, 2018
• 肝移植患者におけるミコフェノール酸の薬物動態に関する検討
  杉本充弘; 木全征典; 佐藤裕紀; 糸原光太郎; 佐藤夕紀; 中川俊作; 米澤淳; 中川貴之; 穴澤貴行; 伊藤孝司; 岡島英明; 海道利実; 上本伸二; 松原和夫, 日本医療薬学会年会講演要旨集(Web), 28, 2018
• 新しい錠剤包装ESOP(easy seal open pack)の使用感とその改良に向けた調査研究
  佐藤夕紀; 梨本俊亮; 武隈洋; 平野卓哉; 野田敏宏; 須田範行; 井関健; 盛本修司; 菅原満, 日本医療薬学会年会講演要旨集(Web), 28, 2018
• テアニンの製剤に含有される成分によるテアニンの消化管吸収増大機構の解明
  佐藤夕紀; 山口和奎; 小川美香子; 武隈洋; 足立知基; 櫻田剛史; 中川公太; 本城政稔; 菅原満, 日本薬剤学会年会講演要旨集(Web), 33rd, 184, 184, 2018
  (公社)日本薬剤学会, Japanese
• オキサ酸を乳化剤として用いたCoenzyme Q10乳剤の性質とその消化管吸収性
  八巻義朗; 西村悠汰; 横山さや香; 佐藤夕紀; 武隈洋; 丸山真吾; 菅原満, 日本薬学会年会要旨集(CD-ROM), 138th, 4, 86, 86, 2018
  (公社)日本薬学会, Japanese
• ヒトK562細胞に対するBCR-ABLチロシンキナーゼインヒビター(TKIs)Washout後持続的細胞増殖抑制効果の検証
  青山 剛; 武隈 洋; 佐藤夕紀; 鷲見正人; 菅原 満, 第31回北海道TDM研究会研究発表会, Nov. 2017
  Japanese, Summary national conference
• Continuous cytotoxic effects of BCR-ABL tyrosine kinase inhibitors (TKIs) after washout in human leukemic K562 cells.
  Aoyama T; Takekuma Y; Sumi M; Sato Y; Sugawara M, 15th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology, 42, 11, 1805, 1813, Sep. 2017
  English, Summary international conference
• ルテインの製剤化による消化管吸収改善
  定村樹; 佐藤夕紀; 梨本俊亮; 鷲見正人; 武隈洋; 菅原満, 日本薬学会北海道支部第144 回例会, May 2017
  Japanese, Summary national conference
• 実務実習前後における薬学生のRIASによるコミュニケーション分析
  森 綾子; 武隈 洋; 小林正紀; 山田勇磨; 佐藤夕紀; 鳴海克哉; 古堅彩子; 菅原 満, 総合技術研究会2017東京大学, 08 Mar. 2017
  Japanese, Summary national conference
• 卵黄レシチンを用いた自己乳化製剤によるクルクミンの消化管吸収改善
  宮下真美; 横山さや香; 佐藤夕紀; 武隈洋; 吉田英人; 菅原満, 日本薬学会年会要旨集(CD-ROM), 137年会, 4, 67, 67, Mar. 2017
  (公社)日本薬学会, Japanese
• 慢性骨髄性白血病治療薬ダサチニブの消化管吸収に及ぼす消化管内pHおよびトランスポーターの影響
  助畑歩; 武隈洋; 鷲見正人; 佐藤夕紀; 菅原満, 日本薬学会年会要旨集(CD-ROM), 137年会, 4, 66, 66, Mar. 2017
  (公社)日本薬学会, Japanese
• 肝遊離細胞サンドイッチ培養法を用いたカルベジロールのグルクロン酸抱合反応に及ぼす光学異性体相互作用の評価
  佐々木萌子; 武隈洋; 佐藤夕紀; 鷲見正人; 菅原満, 日本薬学会年会要旨集(CD-ROM), 137年会, 4, 63, 63, Mar. 2017
  (公社)日本薬学会, Japanese
• オキサ酸を乳化剤として用いたCoenzyme Q10の乳剤化と消化管吸収改善
  横山 さや香; 宮下 真美; 佐藤 夕紀; 武隈 洋; 丸山 真吾; 菅原 満, 日本薬学会年会要旨集, 137年会, 4, 67, 67, Mar. 2017
  (公社)日本薬学会, Japanese
• 脂質異常症治療薬エゼチミブによるα-トコフェロールの消化管吸収抑制とその回避策-ラットおよびヒト血漿中濃度推移からのアプローチ-
  梨本俊亮; 佐藤夕紀; 鷲見正人; 武隈洋; 菅原 満, 第30回北海道TDM研究会研究発表会, 26 Nov. 2016
  Japanese, Summary national conference
• piperacillin/tazobactamとcefepimeの急性腎障害発症に関する後ろ向き観察 比較研究
  門村将太; 佐藤夕紀; 鷲見正人; 武隈 洋; 菅原 満; 福田由布子; 井藤達也, 第30回北海道TDM研究会研究発表会, 26 Nov. 2016
  Japanese, Summary national conference
• コレステロールを含有する乳剤によるコエンザイムQ10の吸収改善
  佐藤 夕紀; 八巻 義朗; 竹川 悠人; 武隈 洋; 菅原 満, 日本薬剤学会年会講演要旨集, 31年会, 186, 186, May 2016
  (公社)日本薬剤学会, Japanese
• テアニン錠剤(速放錠・徐放錠)の溶出性および吸収性の変動要因
  山口和奎; 佐藤夕紀; 武隈 洋; 櫻田剛史; 中川公太; 本城政稔; 菅原 満, 日本薬学会北海道支部第143 回例会, May 2016
  Japanese, Summary national conference
• 小腸コレステロールトランスポーターNPC1L1 (Niemann-Pick C1-Like 1)を介したCoenzyme Q10の消化管吸収改善
  佐藤夕紀; 八巻義朗; 横山さや香; 竹川悠人; 鷲見正人; 武隈洋; 菅原満, 第13回日本コエンザイムQ協会研究会, 02 Feb. 2016
  Japanese, Summary national conference
• α-トコフェロールの吸収動態に及ぼすエゼチミブの影響
  佐藤夕紀; 梨本俊亮; 武隈洋; 菅原満, 第27回ビタミンE研究会, 08 Jan. 2016
  Japanese, Summary national conference
• クロスポビドンを含む錠剤の製剤処方による溶出性の違い
  武隈洋; 石坂悠; 佐藤夕紀; 鷲見正人; 菅原満, 日本医療薬学会年会講演要旨集(Web), 26, 2016
• 可溶性ローヤルゼリー蛋白質MRJP1の腸管透過性評価と吸収成分の生理機能の解析
  本間直幸; 山日千明; 面すみれ; 佐藤夕紀; 菅原満; 森山隆則, 日本未病システム学会学術総会抄録集, 22回, 119, 119, Sep. 2015
  (一社)日本未病システム学会, Japanese
• テアニン製剤(速放錠・徐放錠)を用いた溶出性および吸収性の検討
  山口和奎; 佐藤夕紀; 武隈 洋; 中川公太; 大野智弘; 本城政稔; 菅原 満, 第29回北海道薬物作用談話会, 09 Aug. 2015
  Japanese, Summary national conference
• TDMへの応用を目指した3種のチロシンキナーゼ阻害剤の血中濃度測定法の検証
  助畑 歩; 武隈 洋; 佐藤夕紀; 鷲見正人; 田中寛之; 遠藤 雅之; 菅原 満, 日本薬学会北海道支部第142回例会（札幌）, 16 May 2015
  Japanese, Summary national conference
• エゼチミブ(ゼチーア)が機能性食品成分α-トコフェロールの吸収に与える影響
  梨本 俊亮; 佐藤 夕紀; 鷲見 正人; 武隈 洋; 菅原 満, 日本薬剤学会年会講演要旨集, 30年会, 131, 131, May 2015
  (公社)日本薬剤学会, Japanese
• 乳剤化によるコエンザイムQ10の消化管吸収改善
  佐藤 夕紀; 竹川 悠人; 能登 数馬; 武隈 洋; 菅原 満, 日本薬剤学会年会講演要旨集, 30年会, 136, 136, May 2015
  (公社)日本薬剤学会, Japanese
• Niemann-Pick C1 Like-1(NPC1L1)を標的とした乳剤化による難吸収性物質の吸収改善
  竹川 悠人; 佐藤 夕紀; 鷲見 正人; 武隈 洋; 菅原 満, 日本薬学会年会要旨集, 135年会, 4, 76, 76, Mar. 2015
  (公社)日本薬学会, Japanese
• ローヤルゼリー機能性成分の腸管透過性評価と吸収成分の生理機能の解析
  本間直幸; 山日千明; 面すみれ; 佐藤夕紀; 菅原満; 村田清志; 山口喜久二; 山口喜久二; 森山隆則, 機能性食品と薬理栄養, 8, 5, 436, 436, Dec. 2014
  (株)インフォノーツパブリッシング, Japanese
• ローヤルゼリー機能性成分の腸管透過性評価と吸収成分の生理機能の解析
  本間 直幸; 山日 千明; 面 すみれ; 佐藤 夕紀; 菅原 満; 村田 清志; 山口 喜久二; 森山 隆則, 機能性食品と薬理栄養, 8, 5, 436, 436, Dec. 2014
  (株)インフォノーツパブリッシング, Japanese, Summary national conference
• UDP-グルクロン酸転移酵素の生細胞と細胞破砕液での代謝活性の比較
  池上由麻; 佐藤夕紀; 鷲見正人; 武隈洋; 菅原満, 第28回北海道TDM研究会研究発表会（札幌）, 29 Nov. 2014
  Summary national conference
• UGT1A1 p.P364L変異体および UGT2B7 p.P366L変異体の光学異性体認識性
  依田めぐみ; 佐藤夕紀; 鷲見正人; 武隈洋; 菅原満, 第28回北海道薬物作用談話会（札幌）, 19 Jul. 2014
• 抗ウイルス薬 リバビリンのトランスポーターを介した消化管吸収の解析
  早風郁美; 佐藤夕紀; 鷲見正人; 武隈洋; 菅原満, 第28回北海道薬物作用談話会（札幌）, 19 Jul. 2014
• 中等量エトポシド(VP‐16)/シクロホスファミド(CY)/全身放射線(TBI)前処置レジメンにおけるVP‐16のPK/PD解析による投与量の最適化に関する検討
  TAZAWA YUKI; TAKEKUMA YO; SATO YUKI; SUMI MASATO; KASASHI KUMIKO; ISEKI KEN; SUGAWARA MITSURU, 医療薬学フォーラム講演要旨集, 22nd, 242, Jun. 2014
  Japanese
• 細胞周期変化がエトポシド(VP-16)の殺細胞効果に与える影響
  田澤佑基; 吉岡美咲; 武隈 洋; 佐藤夕紀; 鷲見 正人; 菅原 満, 日本薬学会北海道支部第141回例会（札幌）, 24 May 2014
• Coenzyme Q10の消化管吸収改善
  佐藤夕紀; 能登数馬; 竹川悠人; 鷲見正人; 武隈 洋; 菅原 満, 特定非営利活動法人 日本コエンザイムQ 協会 第11回研究会プログラム（東京）, 28 Jan. 2014
• Caco-2細胞におけるNPC1L1を介したコレステロール輸送の特徴
  阿部沙也華; 佐藤夕紀; 鷲見 正人; 武隈 洋; 菅原 満, 第27回北海道TDM研究会研究発表会（札幌）, 30 Nov. 2013
• 薬物曝露による細胞周期変化が細胞周期依存性の抗癌剤の作用に与える影響
  吉岡美咲; 田澤佑基; 佐藤夕紀; 鷲見 正人; 武隈 洋; 菅原 満, 第27回北海道TDM研究会研究発表会（札幌）, 30 Nov. 2013
• テアニンの体内動態および吸収機構の解明
  亀田佑生; 佐藤夕紀; 鷲見 正人; 武隈 洋; 菅原 満, 第27回北海道TDM研究会研究発表会（札幌）, 30 Nov. 2013
• 機能性食品成分の体内動態特性を考慮した製剤開発に関する研究(Postdoctoral Award受賞講演,再興、再考、創ろう最高の医療の未来)
  佐藤 夕紀, 日本医療薬学会年会講演要旨集, 23, 41, 41, 28 Aug. 2013
  日本医療薬学会, Japanese
• 土-10-O14-09 乳剤化による難吸収性物質の吸収改善 : コレステロール輸送担体NPC1L1の利用(薬物動態,一般演題(口頭)14,再興、再考、創ろう最高の医療の未来)
  竹川 悠人; 佐藤 夕紀; 鷲見 正人; 武隈 洋; 菅原 満, 日本医療薬学会年会講演要旨集, 23, 219, 219, 28 Aug. 2013
  日本医療薬学会, Japanese
• 難吸収性ポリフェノールの乳剤化によるバイオアベイラビリティ改善
  星山博俊; 佐藤夕紀; 鷲見正人; 武隈洋; 菅原満, 第27回北海道薬物作用談話会（江別）, 20 Jul. 2013
• Niemann-pick C1 Like-1 (NPC1L1) を介した難吸収性物質の吸収改善へのアプローチ
  竹川悠人; 佐藤夕紀; 鷲見 正人; 武隈 洋; 菅原 満, 日本薬学会北海道支部第140回例会（札幌）, 18 May 2013
• hOATPs/rOatps を介するミコフェノール酸グルクロナイドの輸送特性の種差
  坂本達彦; 鷲見正人; 佐藤夕紀; 武隈洋; 菅原満, 日本薬学会北海道支部第140回例会（札幌）, May 2013
• 黄斑色素成分ルテインのヒト網膜上皮細胞内への取り込み機構の解明
  佐藤 夕紀; 近藤 有; 武隈 洋; 菅原 満, 日本薬剤学会年会講演要旨集, 28年会, 272, 272, Apr. 2013
  (公社)日本薬剤学会, Japanese
• ヌクレオシドトランスポーターの基質輸送に及ぼすエトポシドの影響
  TAKADA KAZUTERU; TAZAWA YUKI; SATO YUKI; SUMI MASATO; TAKEKUMA YO; SUGAWARA MITSURU, 日本薬学会年会要旨集(CD-ROM), 133年会, 4, 78, 78, Mar. 2013
  (公社)日本薬学会, Japanese
• 一包化調剤時におけるスタチン製剤の保存安定性
  TAKACHI RIKA; ISHIZAKA YU; SATO YUKI; SUMI MASATO; TAKEKUMA YO; SUGAWARA MITSURU, 日本薬学会年会要旨集(CD-ROM), 133年会, 4, 153, 153, Mar. 2013
  (公社)日本薬学会, Japanese
• シタラビンの白血病細胞内移行に対するエトポシドの影響
  高田一輝; 田澤佑基; 佐藤夕紀; 鷲見正人; 武隈洋; 菅原満, 第26回北海道TDM研究会研究発表会（札幌）, Dec. 2012
• 医療現場で新しい薬剤師職能を開拓する活動(病院オペ室での活動)と教員としての研究教育活動
  小林正紀; 山田勇磨; 佐藤夕紀; 井関健, 日本医療薬学会年会講演要旨集, 22nd, 221, 221, 10 Oct. 2012
  日本医療薬学会, Japanese
• テアニンの脳移行に関与するトランスポーター
  川守田渉; 亀田佑生; 佐藤夕紀; 鷲見正人; 武隈 洋; 菅原 満, 第26回北海道薬物作用談話会（札幌）, Jul. 2012
• 粒子径に着目した CoQ10 の乳剤化による吸収改善
  能登数馬; 佐藤夕紀; 武隈 洋; 菅原 満, 日本薬学会北海道支部第138回例会（札幌）, Jun. 2012
• P糖蛋白質(P‐gp)発現白血病由来細胞を用いたエトポシド(VP‐16)/シクロホスファミド(CY)曝露順序の殺細胞効果に及ぼす影響
  USUKUBO IPPEI; TAZAWA YUKI; SATO YUKI; SUMI MASATO; SHIBAYAMA YOSHIHIKO; TAKEKUMA YO; SUGAWARA MITSURU, 日本薬学会年会要旨集, 132年会, 4, 200, 200, Mar. 2012
  (公社)日本薬学会, Japanese
• 中等量VP‐16/シクロホスファミド(CY)/全身放射線(TBI)前処置レジメンにおけるVP‐16のPK/PD解析
  TAZAWA YUKI; MATSUMURA KAZUNORI; SATO YUKI; SUMI MASATO; TAKEKUMA YO; SHIGEMATSU AKIO; KASASHI KUMIKO; YAMADA TAKEHIRO; TANAKA JUNJI; HASHINO SATOSHI; ISEKI KEN; IMAMURA MASAHIRO; SUGAWARA MITSURU, 日本造血細胞移植学会総会プログラム・抄録集, 34th, 224, 01 Feb. 2012
  Japanese
• 抗酸化作用を有する食品成分ルテインの乳化による消化管吸収改善
  佐藤 夕紀; 武隈 洋; 井関 健; 菅原 満, 機能性食品と薬理栄養, 7, 1, 89, 89, Dec. 2011
  (株)インフォノーツパブリッシング, Japanese
• エトポシド/シクロホスファミド併用の殺細胞効果に及ぼす曝露順序の影響 ～白血病由来 K-562 細胞及び P-糖タンパク質発現株を用いた検討～
  田澤佑基; 臼窪一平; 佐藤夕紀; 鷲見正人; 武隈 洋; 菅原 満, 日本薬学会北海道支部第137回例会（札幌）, Dec. 2011
• 同種造血幹細胞移植時における中等量エトポシド(VP‐16)/シクロホスファミド(CY)/全身放射線(TBI)前処置レジメンの検討~VP‐16のPK/PD解析および培養細胞系を用いたVP‐16/CY曝露順序の検討~
  TAZAWA YUKI; MATSUMURA KAZUNORI; SATO YUKI; SUMI MASATO; TAKEKUMA YO; SHIGEMATSU AKIO; KASASHI KUMIKO; YAMADA TAKEHIRO; ISEKI KEN; IMAMURA MASAHIRO; SUGAWARA MITSURU, TDM研究, 28, 3, s203, s203, Jun. 2011
  (一社)日本TDM学会, Japanese
• テアニンの消化管吸収に関与するトランスポーター
  川守田 渉; 堀田 雄也; 佐藤 夕紀; 鷲見 正人; 武隈 洋; 菅原 満, 日本薬学会年会要旨集, 131年会, 4, 165, 165, Mar. 2011
  (公社)日本薬学会, Japanese
• ルテインの乳化による消化管吸収改善
  佐藤 夕紀; 鈴木 里彩; 武隈 洋; 井関 健; 菅原 満, 日本薬学会年会要旨集, 131年会, 4, 165, 165, Mar. 2011
  (公社)日本薬学会, Japanese
• 白血病由来細胞を用いたエトポシド(VP‐16)/シクロホスファミド(CY)曝露順序の殺細胞効果への影響
  TAZAWA YUKI; MATSUMURA ISSEN; KASASHI KUMIKO; SATO YUKI; SUMI MASATO; TAKEKUMA YO; ISEKI KEN; SUGAWARA MITSURU, 日本薬学会年会要旨集, 131年会, 4, 178, 178, Mar. 2011
  (公社)日本薬学会, Japanese
• ルテインの消化管における吸収挙動:トランスポータの関与
  佐藤夕紀; 澁谷智美; 小林正紀; 板垣史郎; 野田敏宏; 水野智; 井関健, 薬剤学, 69, Supplement, 98, 30 Apr. 2009
  Japanese
• 21I-13 ルテイン長期投与による肺蓄積機構の解明(薬物動態(基礎・臨床・遺伝子多型),来るべき時代への道を拓く)
  澁谷 智美; 佐藤 夕紀; 小林 正紀; 板垣 史郎; 平野 剛; 井関 健, 日本医療薬学会年会講演要旨集, 18, 0, 280, 280, 01 Sep. 2008
  日本医療薬学会, Japanese
• 29-C1-10-4 ルテインの吸収動態の解明と酸化障害抑制効果に対する検討(薬物相互作用・薬物動態,社会の期待に応える医療薬学を)
  佐藤 夕紀; 澁谷 智美; 小林 正紀; 板垣 史郎; 平野 剛; 井関 健, 日本医療薬学会年会講演要旨集, 17, 0, 196, 196, 01 Sep. 2007
  日本医療薬学会, Japanese

• 薬物動態学 = Pharmacokinetics
  永田 将司編集、高田龍平、佐藤夕紀、山崎啓之、山折大、桂敏也、大野能之、荒木拓也、平井利典、土岐浩介、山崎伸吾, 吸収
  メジカルビュー社, Mar. 2025, 9784758322232, xii, 274p, Japanese, [Contributor]
• 地域包括ケアで薬立つ4 ELEMENTS実践ガイド
  松原和夫; 深津祥央; 佐藤夕紀; 中川貴之; 中川俊作; 大村友博; 今井哲司; 萱野勇一郎; 吉田優子; 米澤淳; 池見泰明; 尾崎淳子
  南山堂, Mar. 2020, 9784525783518, viii, 276p, Japanese, [Contributor]

• 〔主要な業績〕ヒアルロン酸2糖の定量を目的とした分析条件の最適化
  青栁空馬; 佐藤夕紀; 梨本俊亮; 柏木仁; 武隈洋; 菅原満
  日本薬学会北海道支部第153回例会(第73回北海道薬学大会), 30 May 2026, Japanese, Oral presentation
  30 May 2026 - 31 May 2026
• 〔主要な業績〕Coenzyme Q10によるバンコマイシン誘発性腎障害に対する抑制効果
  佐藤夕紀; 武内咲知枝; 梨本俊亮; 今井俊吾; 柏木仁; 武隈洋; 菅原満
  第22日本コエンザイムQ協会研究会(第38回日本酸化ストレス学会関東支部会), 18 Feb. 2026, Japanese, Poster presentation
• 〔主要な業績〕レプチンがヒトリンパ管内皮細胞の細胞膜透過性に与える影響
  佐藤夕紀; 船戸美汐; 柏木仁; 梨本俊亮; 武隈洋; 菅原満
  第35回日本医療薬学会年会, 23 Nov. 2025, Japanese, Poster presentation
  22 Nov. 2025 - 24 Nov. 2025
• 〔Major achievements〕Development of an evaluation system using intestinal organoids for drug efflux transport analysis by an imaging approach
  Yuki Sato; Chihiro Koseki; Takehiko Ishikawa; Yuki Yokoi; Kiminori Nakamura; Naoyuki Honma; Takanori Moriyama; Hitoshi Kashiwagi; Mitsuru Sugawara
  日本薬物動態学会第40回年会, 22 Oct. 2025, English, Poster presentation
  20 Oct. 2025 - 23 Oct. 2025
• 〔主要な業績〕小腸オルガノイドapical-basal反転培養方法の確立
  浅川綾汰; 佐藤夕紀; 柏木仁; 梨本俊亮; 武隈洋; 菅原満
  第8回フレッシャーズ・カンファランス, 21 Jun. 2025, Japanese, Oral presentation
  21 Jun. 2025 - 22 Jun. 2025
• 〔主要な業績〕アミノ酸トランスポーターSNAT4を介したエンドサイトーシスによる基質修飾リポソームの取り込み
  松山琳空; 佐藤夕紀; 藤田聡; 丸山真吾; 梨本俊亮; 柏木仁; 武隈洋; 菅原満
  日本薬剤学会第40年会, 22 May 2025, Japanese, Oral presentation
  22 May 2025 - 24 May 2025
• 抗酸化物質コエンザイムQ10のバンコマイシン誘発性腎障害抑制効果
  武内咲知枝; 佐藤夕紀; 梨本俊亮; 柏木仁; 武隈洋; 菅原満
  第31回日本医療薬学会年会, 04 Nov. 2024, Japanese, Oral presentation
  02 Nov. 2024 - 04 Nov. 2024
• 〔主要な業績〕ヒアルロン酸オリゴ糖の同時定量法の確立と血漿中濃度推移の評価
  佐藤夕紀
  第１０回日本薬剤学会経口吸収フォーカスグループ合宿討論会, 11 Oct. 2024, Japanese, Oral presentation
  10 Oct. 2024 - 11 Oct. 2024, [Invited]
• 〔主要な業績〕低吸収性を示す機能性食品成分の吸収機構の解明と その特性を考慮した製剤開発にむけて
  佐藤夕紀
  徳島大学, 26 Jul. 2024, Japanese, Invited oral presentation
  [Invited]
• 〔主要な業績〕ヒアルロン酸4,6,8糖の同時定量法の確立
  佐藤 夕紀; 高林 直央; 青柳 空馬; 梨本 俊亮; 柏木 仁; 武隈 洋; 菅原 満
  日本薬剤学会年会講演要旨集, May 2024, (公社)日本薬剤学会, Japanese
  May 2024 - May 2024
• Evaluation of absorption and properties of emulsion and self-emulsifying drug delivery system of cyclosporine A
  佐藤夕紀; 木下祐介; 上村聡; 丸山真吾; 武隈洋; 菅原満; 菅原満
  日本薬剤学会年会講演要旨集(CD-ROM), May 2023, (公社)日本薬剤学会, Japanese
  May 2023 - May 2023
• 〔Major achievements〕Development of a method of simultaneous determination of orally administered hyaluronan oligosaccharides
  高林直央; 佐藤夕紀; 柏木仁; 梨本俊亮; 武隈洋; 菅原満; 菅原満
  バイオメディカル分析科学シンポジウム講演要旨集, 2023, Japanese
  2023 - 2023
• 〔主要な業績〕LC/MS/MSを用いたリネゾリドならびにテジゾリドのヒト血漿中濃度同時定量法の確立
  佐藤夕紀; 大聖貴之; 柏木仁; 今井俊吾; 武隈洋; 菅原満; 菅原満
  日本医療薬学会年会講演要旨集(Web), 2022
  2022 - 2022
• 〔主要な業績〕吸収トランスポーターの機能解析へのエンテロイドの応用
  島田 美紀子; 佐藤 夕紀; 柏木 仁; 今井 俊吾; 武隈 洋; 菅原 満
  日本薬学会年会要旨集, Mar. 2021, (公社)日本薬学会, Japanese
  Mar. 2021 - Mar. 2021
• 〔主要な業績〕卵黄レシチンを用いた乳剤化に適した化合物の物理化学的特性
  鳥山 竜也; 佐藤 夕紀; 柏木 仁; 今井 俊吾; 武隈 洋; 菅原 満
  日本薬学会年会要旨集, Mar. 2021, (公社)日本薬学会, Japanese
  Mar. 2021 - Mar. 2021
• 〔主要な業績〕経口摂取されたヒアルロン酸の消化管吸収評価
  佐藤夕紀
  ヒアルロン酸機能性研究会第５回学術大会, 26 Sep. 2019, Japanese, Invited oral presentation
  [Invited]
• 〔主要な業績〕機能性食品成分の吸収動態特性を踏まえた製剤学的アプローチ
  佐藤夕紀
  日本食品科学工学会第６６回大会, 31 Aug. 2019, Japanese, Invited oral presentation
  29 Aug. 2019 - 31 Aug. 2019, [Invited]
• 〔主要な業績〕日本人リウマチ患者の服薬アドヒアランスが薬物治療の効果に及ぼす影響
  中川俊作; 中石真由美; 橋下求; 伊藤宣; 山本渉; 中嶋蘭; 田中真生; 藤井隆夫; 佐藤夕紀; 大村友博; 今井哲司; 中川貴之; 米澤淳; 今井博久; 三森経世; 松原和夫
  第12回次世代を担う若手医療薬科学シンポジウム, Sep. 2018, Japanese, Oral presentation
  [Domestic Conference]
• 〔主要な業績〕機能性食品成分ルテインとコエンザイムQ10の製剤学的工夫による消化管吸収改善
  佐藤夕紀; 定村樹; 八巻義朗; 横山さや香; 梨本俊亮; 武隈洋; 菅原満
  第12回次世代を担う若手医療薬科学シンポジウム, Sep. 2018, Japanese, Oral presentation
  [Domestic Conference]
• 〔Major achievements〕.
  Yuki Sato
  The 13th Meeting of the Japan Transporter Research Association, 21 Jul. 2018, Japanese, Poster presentation
  [Domestic Conference]
• 〔主要な業績〕小学校での薬物乱用防止教室を通して見えてきたことと今後の課題
  佐藤夕紀; 田中早苗; 中山章; 田中稔泰; 菅原満; 宮下元樹
  北海道薬剤師会学薬部会(第65回北海道薬学大会), 13 May 2018, Japanese, Oral presentation
  [Domestic Conference]
• 〔主要な業績〕オキサ酸を用いた乳剤化によるクルクミンの吸収改善と消化管への影響の評価
  西村悠汰; 八巻義朗; 佐藤夕紀; 武隈洋; 丸山真吾; 菅原満
  日本薬学会北海道支部第145回例会(第65回北海道薬学大会), 12 May 2018, Japanese, Oral presentation
  [Domestic Conference]
• 〔Major achievements〕機能性食品成分ルテインの製剤化による吸収改善
  佐藤夕紀
  アグリバイオ, Apr. 2018, Japanese
  Apr. 2018 - Apr. 2018, [Invited]
• 〔Major achievements〕オキサ酸を乳化剤として用いたCoenzyme Q10乳剤の性質とその消化管吸収性
  八巻 義朗; 西村 悠汰; 横山 さや香; 佐藤 夕紀; 武隈 洋; 丸山 真吾; 菅原 満
  日本薬学会年会要旨集, Mar. 2018, Japanese, Oral presentation
  [Domestic Conference]
• 〔Major achievements〕テアニンの製剤に含有される成分によるテアニンの消化管吸収増大機構の解明
  佐藤夕紀; 山口和奎; 小川美香子; 武隈洋; 足立知基; 櫻田剛史; 中川公太; 本城政稔; 菅原満
  日本薬剤学会年会講演要旨集(Web), 2018, Japanese
• 〔Major achievements〕Emulsification using oxa acids for oral administration and improvement of intestinal absorption of Coenzyme Q10.
  Sato Y; Yokoyama S; Yamaki Y; Miyashita M; Takekuma Y; Maruyama S; Sugawara M
  8th Joint Meeting for Free Radical Research Australasia and Japan with International Symposium on Coenzyme Q10, Dec. 2017, English, Poster presentation
  [International presentation]
• 〔主要な業績〕低吸収性を示す機能性食品成分の消化管吸収機構の解明と吸収特性を考慮した製剤開発
  佐藤夕紀
  日本薬学会北海道支部第144回例会(第64回北海道薬学大会), May 2017, Japanese, Invited oral presentation
  [Invited], [Domestic Conference]
• 〔主要な業績〕ルテインの製剤化による消化管吸収改善
  定村樹; 佐藤夕紀; 梨本俊亮; 鷲見正人; 武隈洋; 菅原満
  日本薬学会北海道支部第144回例会(第64回北海道薬学大会), May 2017, Japanese, Oral presentation
  [Domestic Conference]
• 〔Major achievements〕テアニン錠剤(速放錠・徐放錠)の溶出性および吸収性の変動要因
  山口 和奎; 佐藤 夕紀; 武隈 洋; 櫻田 剛史; 中川 公太; 本城 政稔; 菅原 満
  日本薬学会年会要旨集, Mar. 2017, Japanese
• 〔Major achievements〕オキサ酸を乳化剤として用いたCoenzyme Q10の乳剤化と消化管吸収改善
  横山 さや香; 宮下 真美; 佐藤 夕紀; 武隈 洋; 丸山 真吾; 菅原 満
  日本薬学会年会要旨集, Mar. 2017, Japanese
• 〔Major achievements〕卵黄レシチンを用いた自己乳化製剤によるクルクミンの消化管吸収改善
  宮下 真美; 横山 さや香; 佐藤 夕紀; 武隈 洋; 吉田 英人; 菅原 満
  日本薬学会年会要旨集, Mar. 2017, Japanese
• 〔主要な業績〕機能性食品コエンザイムQ10とルテインの消化管吸収改善
  佐藤夕紀
  日本薬剤学会 第7回経口吸収フォーカスグループ合宿討論会, Dec. 2016, Japanese, Oral presentation
  [Domestic Conference]
• 〔主要な業績〕脂質異常症治療薬エゼチミブによるα-トコフェロールの消化管吸収抑制とその回避策-ラットおよびヒト血漿中濃度推移からのアプローチ-.
  梨本俊亮; 佐藤夕紀; 鷲見正人; 武隈洋; 菅原満
  第30回北海道TDM研究会研究発表会, Nov. 2016, Japanese, Oral presentation
  [Domestic Conference]
• 〔主要な業績〕正しい手の洗い方に関する授業を通して感じた工夫の必要性と今後の課題
  佐藤夕紀; 飯村髙延; 河野かおり; 神与博; 日戸靖彦; 田中早苗; 中山章; 田中稔泰; 菅原満; 宮下元樹
  第96回北海道医学大会 学校保健分科会 第51回北海道学校保健学会, Oct. 2016, Japanese, Oral presentation
  [Domestic Conference]
• クロスポビドンを含む錠剤の製剤処方による溶出性の違い
  武隈洋; 石坂悠; 佐藤夕紀; 鷲見正人; 菅原満
  第26回日本医療薬学会年会, Sep. 2016, Japanese, Oral presentation
  [Domestic Conference]
• 〔主要な業績〕食品成分の吸収評価と改善
  佐藤夕紀
  ライフサイエンスセミナー シーズ公開会, Jul. 2016, Japanese, Public discourse
  [Invited], [Domestic Conference]
• 〔主要な業績〕小学校での授業を通して見えてきたことと今後の課題
  佐藤夕紀; 田中早苗; 中山章; 田中稔泰; 菅原満; 宮下元樹
  北海道薬剤師会学薬部会(第63回北海道薬学大会), May 2016, Japanese, Oral presentation
  [Domestic Conference]
• 〔Major achievements〕コレステロールを含有する乳剤によるコエンザイムQ10の吸収改善
  佐藤夕紀; 八巻義朗; 竹川悠人; 武隈洋; 菅原満
  日本薬剤学会年会講演要旨集(Web), May 2016, Japanese
• 〔Major achievements〕脂質異常症治療薬エゼチミブによるα‐トコフェロールの消化管吸収抑制とその回避策
  梨本俊亮; 佐藤夕紀; 鷲見正人; 武隈洋; 菅原満
  日本薬学会年会要旨集(CD-ROM), Mar. 2016, Japanese
• 〔主要な業績〕小腸コレステロールトランスポーターNPC1L1 (Niemann-Pick C1-Like 1)を介したCoenzyme Q10の消化管吸収改善
  佐藤夕紀; 八巻義朗; 横山さや香; 竹川悠人; 鷲見正人; 武隈洋; 菅原満
  第13回日本コエンザイムQ協会研究会, Feb. 2016, Japanese, Oral presentation
  [Domestic Conference]
• 〔主要な業績〕α-トコフェロールの吸収動態に及ぼすエゼチミブの影響
  佐藤夕紀; 梨本俊亮; 武隈洋; 菅原満
  第27回ビタミンE研究会, Jan. 2016, Japanese, Oral presentation
  [Domestic Conference]
• 〔主要な業績〕機能性食品成分の吸収特性を考慮した製剤開発
  佐藤夕紀
  宮崎大学 農工連携製剤研究会, Jan. 2016, Japanese, Public discourse
  [Invited], [Domestic Conference]
• 〔Major achievements〕エゼチミブ(ゼチーア)が機能性食品成分α-トコフェロールの吸収に与える影響
  梨本 俊亮; 佐藤 夕紀; 鷲見 正人; 武隈 洋; 菅原 満
  日本薬剤学会年会講演要旨集, May 2015, Japanese, Oral presentation
  [Domestic Conference]
• 〔Major achievements〕乳剤化によるコエンザイムQ10の消化管吸収改善
  佐藤 夕紀; 竹川 悠人; 能登 数馬; 武隈 洋; 菅原 満
  日本薬剤学会年会講演要旨集, May 2015, Japanese, Oral presentation
  [Domestic Conference]
• 〔Major achievements〕Niemann‐Pick C1Like‐1(NPC1L1)を標的とした乳剤化による難吸収性物質の吸収改善
  竹川悠人; 佐藤夕紀; 鷲見正人; 武隈洋; 菅原満
  日本薬学会年会要旨集(CD-ROM), Mar. 2015, Japanese, Oral presentation
  [Domestic Conference]
• トランスポーターを介した低吸収性成分の吸収改善の可能性
  佐藤夕紀
  ノーステック財団「研究開発助成事業」研究開発事例報告会, Feb. 2015
  [Invited], [Domestic Conference]
• 〔主要な業績〕Coenzyme Q10の消化管吸収改善
  佐藤夕紀; 能登数馬; 武隈洋; 井関健; 菅原満
  日本コエンザイムQ協会第11回研究会, Jan. 2014, Japanese, Oral presentation
  [Domestic Conference]
• 〔主要な業績〕機能性食品成分の体内動態特性を考慮した製剤開発に関する研究(Postdoctoral Award受賞講演,再興、再考、創ろう最高の医療の未来)
  佐藤夕紀
  第23回日本医療薬学会年会, Sep. 2013, Japanese, Invited oral presentation
  [Invited], [Domestic Conference]
• 〔主要な業績〕土-10-O14-09 乳剤化による難吸収性物質の吸収改善 : コレステロール輸送担体NPC1L1の利用(薬物動態,一般演題(口頭)14,再興、再考、創ろう最高の医療の未来)
  竹川 悠人; 佐藤 夕紀; 鷲見 正人; 武隈 洋; 菅原 満
  第23回日本医療薬学会年会, Sep. 2013, Japanese, Oral presentation
  [Domestic Conference]
• 〔Major achievements〕乳剤化による難吸収性物質の吸収改善~コレステロール輸送担体NPC1L1の利用~
  竹川悠人; 佐藤夕紀; 鷲見正人; 武隈洋; 菅原満
  日本医療薬学会年会講演要旨集, 28 Aug. 2013, Japanese
• 〔Major achievements〕機能性食品成分の体内動態特性を考慮した製剤開発に関する研究
  佐藤夕紀
  日本医療薬学会年会講演要旨集, 28 Aug. 2013, Japanese
• 〔主要な業績〕ルテインの機能性とその活用について
  佐藤夕紀
  第4回「食と健康」研究会, Jun. 2013, Japanese, Invited oral presentation
  [Invited], [Domestic Conference]
• 〔Major achievements〕黄斑色素成分ルテインのヒト網膜上皮細胞内への取り込み機構の解明
  SATO YUKI; KONDO YUTAKA; TAKEKUMA YO; SUGAWARA MITSURU
  日本薬剤学会年会講演要旨集(Web), 26 Apr. 2013, Japanese
• S1I-2-4 医療現場で新しい薬剤師職能を開拓する活動(病院オペ室での活動)と教員としての研究教育活動(シンポジウム S1I-2 薬学・薬剤師教育の充実、薬剤師職能の向上、医療薬学の発展のために臨床系・実務家教員は何をすべきか?,岐路に立つ医療〜千年紀の目覚め〜よみがえれ!ニッポン!薬の改革は我らが手で!)
  小林 正紀; 山田 勇磨; 佐藤 夕紀; 井関 健
  第22回日本医療薬学会年会, Oct. 2012, Japanese, Invited oral presentation
  [Invited], [Domestic Conference]
• 〔Major achievements〕抗酸化作用を有する食品成分ルテインの乳化による消化管吸収改善
  SATO YUKI; TAKEKUMA YO; ISEKI KEN; SUGAWARA MITSURU
  機能性食品と薬理栄養, 10 Dec. 2011, Japanese
• 〔Major achievements〕機能性食品成分ルテインの乳化による消化管吸収の改善
  SATO YUKI; SUZUKI RISA; TAKEKUMA YO; ISEKI KEN; SUGAWARA MITSURU
  医療薬学フォーラム講演要旨集, Jul. 2011, Japanese
• テアニンの消化管吸収に関与するトランスポーター
  KAWAMORITA WATARU; HOTTA YUYA; SATO YUKI; SUMI MASATO; TAKEKUMA YO; SUGAWARA MITSURU
  日本薬学会年会要旨集, 05 Mar. 2011, Japanese
• ルテインの乳化による消化管吸収改善
  SATO YUKI; SUZUKI RISA; TAKEKUMA YO; ISEKI KEN; SUGAWARA MITSURU
  日本薬学会年会要旨集, 05 Mar. 2011, Japanese
• ルテインの消化管における吸収挙動:トランスポータの関与
  SATO YUKI; SHIBUYA TOMOMI; KOBAYASHI MASAKI; ITAGAKI SHIRO; NODA TOSHIHIRO; MIZUNO SATOSHI; ISEKI KEN
  薬剤学, 30 Apr. 2009, Japanese
• ルテインの吸収・分布動態の解明
  佐藤 夕紀; 澁谷 智美; 小林 正紀; 板垣 史郎; 野田 敏宏; 水野 智; 平野 剛; 井関 健
  第23回日本薬物動態学会年会, Oct. 2008, Japanese
  [Domestic Conference]
• 21I-13 ルテイン長期投与による肺蓄積機構の解明(薬物動態(基礎・臨床・遺伝子多型),来るべき時代への道を拓く)
  澁谷 智美; 佐藤 夕紀; 小林 正紀; 板垣 史郎; 平野 剛; 井関 健
  日本医療薬学会年会講演要旨集, 01 Sep. 2008, Japanese
• ルテイン長期投与による肺蓄積機構の解明
  SHIBUYA TOMOMI; SATO YUKI; KOBAYASHI MASAKI; ITAGAKI SHIRO; HIRANO TSUYOSHI; ISEKI KEN
  日本医療薬学会年会講演要旨集, 01 Sep. 2008, Japanese
• 29-C1-10-4 ルテインの吸収動態の解明と酸化障害抑制効果に対する検討(薬物相互作用・薬物動態,社会の期待に応える医療薬学を)
  佐藤 夕紀; 澁谷 智美; 小林 正紀; 板垣 史郎; 平野 剛; 井関 健
  日本医療薬学会年会講演要旨集, 01 Sep. 2007, Japanese
• ルテインの吸収動態の解明と酸化障害抑制効果に対する検討
  SATO YUKI; SHIBUYA TOMOMI; KOBAYASHI MASAKI; ITAGAKI SHIRO; HIRANO TSUYOSHI; ISEKI KEN
  日本医療薬学会年会講演要旨集, 01 Sep. 2007, Japanese

• 医療情報解析演習, 2024年, 学士課程, 薬学部
• 薬剤学Ⅲ, 2024年, 学士課程, 薬学部
• 実務実習事前実習, 2024年, 学士課程, 薬学部
• OSCE対応演習, 2024年, 学士課程, 薬学部

• ビタミンE研究会
• トランスポーター研究会
• THE PHARMACEUTICAL SOCIETY OF JAPAN
• JAPANESE SOCIETY OF PHARMACEUTICAL HEALTH CARE AND SCIENCES
• THE JAPANESE SOCIETY FOR THE STUDY OF XENOBIOTICS
• THE ACADEMY OF PHARMACEUTICAL SCIENCE AND TECHNOLOGY, JAPAN
• 日本病院薬剤師会

• 腸への作用を期待したヒアルロン酸オリゴ糖の製剤開発
  札幌イノベーション事業化支援補助金（札幌イノベーション事業化支援補助金【産学連携枠】）
  Jul. 2026 - Mar. 2027
  佐藤夕紀
  公益財団法人 北海道科学技術総合振興センター, 北海道大学, Principal investigator
• 唾液中薬物濃度モニタリングが適用可能な薬物の選択方法の確立
  科学研究費助成事業
  Apr. 2024 - Mar. 2027
  武隈 洋; 佐藤 夕紀; 柏木 仁
  日本学術振興会, 基盤研究(C), 北海道大学, Coinvestigator, 24K09933
• 皮膚への作用を期待したヒアルロン酸オリゴ糖の製剤開発
  札幌バイオシーズ事業化支援事業（札幌バイオシーズ事業化支援補助金【産学連携枠】）
  Aug. 2025 - Mar. 2026
  佐藤夕紀
  公益財団法人 北海道科学技術総合振興センター, 北海道大学, Principal investigator
• ヒアルロン酸オリゴ糖の同時定量法による体内動態特性の解析と腸管免疫系への関与
  Apr. 2025 - Mar. 2026
  佐藤夕紀
  公益財団法人 日本食品化学研究振興財団, 北海道大学, Principal investigator
• 三次元培養系小腸オルガノイドを用いた糖質と脂質の吸収を視覚的かつ定量的に検出する系の確立
  Apr. 2025 - Mar. 2026
  佐藤夕紀
  公益財団法人 飯島藤十郎記念食品科学振興財団, 北海道大学, Principal investigator
• リンパ浮腫と肥満とコレステロール動態の関連性の実態解明とその予防策の構築
  科学研究費助成事業
  Apr. 2023 - Mar. 2026
  佐藤 夕紀
  日本学術振興会, 基盤研究(C), 北海道大学, Principal investigator, 23K06207
• ヒアルロン酸オリゴ糖の同時定量法による体内動態特性の解析と小腸免疫系への関与
  Apr. 2024 - Mar. 2025
  佐藤夕紀
  公益財団法人 日本食品化学研究振興財団, 北海道大学, Principal investigator
• ヒアルロン酸オリゴ糖の簡易微量定量法の確立と体内動態特性の解析
  研究助成金
  Apr. 2023 - Mar. 2024
  佐藤夕紀
  公益財団法人 日本食品化学研究振興財団, 北海道大学大学院薬学研究院, Principal investigator
• オキサゾリジノン系抗MRSA薬の唾液中濃度による治療モニタリングと投与量最適化
  科学研究費助成事業 基盤研究(C)
  Apr. 2021 - Mar. 2024
  武隈 洋; 佐藤 夕紀; 今井 俊吾
  今年度は、リネゾリド（LZD）およびテジゾリド（TZD）の血中濃度モニタリングの代替指標として唾液中濃度が利用できるかを検証するための準備として、ラットを用いて唾液中への薬物移行性を評価する系の確立に着手した。ラットをウレタン麻酔した状態で、顕微鏡下で顎下腺の口腔内開口部へカニュレーションを施した。定量に十分な唾液量を採取するために、既報（Nezu A. et al., Exp. Physiol., 104, 61-69 (2019)）を参考にアセチルコリンを大腿静脈へ施したカニュレーションからシリンジポンプを用いて投与した。投与速度と唾液の分泌量を評価したところ、260 nmol/minでアセチルコリンを投与すると10分間で200μL以上唾液を採取可能であった。
  並行して、母集団薬物動態から乖離する患者の要因の抽出を検証するために共同研究者が入手したリアルワールドデータ株式会社が提供する電子カルテ由来の診療情報データベースを用いた解析を行った。対象薬剤は特定薬剤治療管理料１の対象ではないため一般に血中濃度モニタリングは実施されていない。そのため、血中濃度データは格納されていないので、LZD血中濃度と発症率の相関が報告されている血小板減少症を代替指標として、血小板減少症の発症リスクを1,399症例を対象として解析した。その結果、LZDの14日以上の長期投与、体重45kg未満、eGFR 30mL/min/1.73m2がリスク因子として抽出された。特に医療ビッグデータを利用することで症例が多く確保できたので、既報では解析できなかったeGFRの層別解析が可能となり、LZDが7日未満の投与であっても、eGFR 15mL/min/1.73m2でリスクが上昇することを明らかにした。
  日本学術振興会, 基盤研究(C), 北海道大学, Coinvestigator, 21K06684
• 小腸オルガノイドを利用した吸収と排出に与える影響を視覚的かつ定量的に検出する系の確立
  持田記念研究助成金
  Dec. 2022 - Dec. 2023
  佐藤夕紀
  公益財団法人 持田記念医学薬学振興財団, 北海道大学大学院薬学研究院, Principal investigator
• 低吸収性機能性食品成分の牛乳成分ミセルを利用した吸収改善法の確立
  札幌ライフサイエンス産業事業 研究シーズ発掘補助金(札幌タレント補助金)
  Aug. 2022 - Mar. 2023
  佐藤夕紀
  公益財団法人 北海道科学技術総合振興センター, 北海道大学, Principal investigator, Competitive research funding, ST-1-24
• Study of the relationship between lymph edema, obesity and cholesterol
  Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)
  Apr. 2020 - Mar. 2023
  Sato Yuki
  In this study, we focused on the dynamics of fat-soluble components such as adipocytes and cholesterol and investigated to clarify the effects of obesity. To date, using human lymphatic endothelial cells, we have confirmed changes in the permeability of albumin and other substances that accompany changes in VE-cadherin following leptin exposure. In human lymphatic endothelial cells, it was confirmed that leptin exposure slightly increased the permeation amount of fluorescent-labeled albumin compared to the control group. In addition, we constructed a transporter expression system using Xenopus laevis oocytes to study cholesterol dynamics in detail.
  Japan Society for the Promotion of Science, Grant-in-Aid for Scientific Research (C), Hokkaido University, Principal investigator, Competitive research funding, 20K07153
• ルテインの黄斑における濃度と機能発現との関連性に関する研究
  Apr. 2018 - Mar. 2019
  佐藤夕紀
  一般財団法人 藤原記念財団, 京都大学医学部附属病院, Principal investigator, Competitive research funding
• 種々の大きさのヒアルロン酸摂取後のリンパ液・血液への移行性と腸管免疫系への関与
  Apr. 2018 - Mar. 2019
  佐藤夕紀
  一般財団法人 旗影会, Principal investigator, Competitive research funding
• Study of formulation development based on the properties of functional food components
  Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)
  Apr. 2016 - Mar. 2019
  Sato Yuki
  We have focused on the absorption mechanism of antioxidative food components that show low bioavailability and we have made efforts to improve their poor absorption based on their pharmacokinetic properties. In this study, we performed the enhancement of absorption of coenzyme Q10 (CoQ10), curcumin and lutein to prepare some formulations. We focused on the component of emulsion to improve the absorption. We found that the higher plasma concentrations of CoQ10 and curcumin were obtained by an emulsion containing a surfactant ova acids, new materials of surfactants. We also prepared a solid dispersion and a self-emulsifying drug delivery system for improvement of lutein absorption. The absorption of lutein was evaluated by its cumulative amount in lymph. Our data showed that lutein is transferred into the lymph stream from the small intestine rather than into the blood stream. Further investigations to improve the absorption of these components are in progress.
  Japan Society for the Promotion of Science, Grant-in-Aid for Scientific Research (C), Principal investigator, Competitive research funding, 16K00842
• 経口投与されたヒアルロン酸の血液・リンパ液への移行性および小腸の免疫系への関与
  Apr. 2017 - Mar. 2018
  佐藤夕紀
  一般財団法人 旗影会, Principal investigator, Competitive research funding
• 機能性食品成分ルテインの消化管吸収改善に最適な製剤の開発
  札幌ライフサイエンス産業事業 研究シーズ発掘補助金(札幌タレント補助金)
  Aug. 2016 - Mar. 2017
  佐藤夕紀
  公益財団法人 北海道科学技術総合振興センター, Principal investigator, Competitive research funding
• 食品機能性成分の吸収・活性評価プラットフォームの構築
  地域イノベーション戦略研究開発委託事業
  Apr. 2015 - Mar. 2017
  森山隆則
  公益財団法人 北海道科学技術総合振興センター, Competitive research funding
• Niemann-Pick C1 Like-1 (NPC1L1)を利用した難吸収性食品成分の消化管吸収改善法の開発
  2016 - 2017
  佐藤夕紀
  公益財団法人 東洋食品研究所, Principal investigator, Competitive research funding
• Improvement of intestinal absorption of poorly-absorbed functional food components based on the property of its pharmacokinetics
  Grants-in-Aid for Scientific Research Grant-in-Aid for Young Scientists (B)
  01 Apr. 2014 - 31 Mar. 2016
  SATO Yuki
  We investigated the uptake mechanism of a substrate of NPC1L1 in the lipid emulsion particles and whether these particles containing cholesterol can improve the intestinal absorption of other poorly-absorbed lipoohilic (water-insoluble) components via NPC1L1. In this study, our results suggested that not only cholesterol but also some components in lipid particles are taken up into enterocytes via NPC1L1. We also examined an approach to improve intestinal absorption of a poorly absorbed water-insoluble component, coenzyme Q10 (CoQ10), by this mechanism. The uptake of CoQ10 in lipid emulsion particles containing cholesterol was significantly increased compared to that without cholesterol. Its increased uptake was significantly inhibited by ezetimibe. There is a potential for improvement of the absorption of poorly absorbed components by lipid emulsion particles containing cholesterol.
  Japan Society for the Promotion of Science, Grant-in-Aid for Young Scientists (B), Hokkaido University, Principal investigator, Competitive research funding, 26860092
• より安全なセルフメディケーションのための吸収改善・効果改善を期待した製剤の開発
  調査・研究助成金
  2015 - 2016
  佐藤夕紀
  公益財団法人 一般用医薬品セルフメディケーション振興財団, 北海道大学, Principal investigator, Competitive research funding
• トランスポータNPC1L1を介した難水溶性物質の消化管吸収改善への新規アプローチ
  学術研究奨励金
  2014 - Jun. 2015
  佐藤夕紀
  公益財団法人 三島海雲記念財団, Principal investigator, Competitive research funding
• レシチンによる難溶性薬物の消化管吸収改善効果～卵黄レシチンと大豆レシチンの比較
  Apr. 2014 - Mar. 2015
  菅原満
  一般財団法人 旗影会, Competitive research funding
• 乳剤粒子を効率よく細胞内へ取り込む機構を利用した新しい経口吸収改善法の確立
  調査・研究助成金
  2014 - 2015
  佐藤夕紀
  公益財団法人 一般用医薬品セルフメディケーション振興財団, Principal investigator, Competitive research funding
• Pharmaceutical development of functional food components based on pharmacokinetic properties
  Grants-in-Aid for Scientific Research Grant-in-Aid for Young Scientists (B)
  01 Apr. 2012 - 31 Mar. 2014
  SATO YUKI
  Preventive medicine and anti-aging medicine have received much attention recently due to increases in the proportion of elderly people in the population and patients with lifestyle diseases. We investigated the absorption mechanism of lutein, a functional food component, in detail. Ezetimibe, an inhibitor of NPC1L1 (Niemann-Pick C1-Like 1), inhibited up to 40% of lutein accumulation by Caco-2 cell monolayers. Our results showed that lutein absorption is, at least in part, mediated by influx transporter NPC1L1. We then prepared some emulsions and investigated the effect the improvement the absorption. Our study suggests that Bile and emulsion formulation are essential for absorption of Coenzyme Q10 (CoQ10), a lipophilic food component. Highly lipophilic compounds like CoQ10 would diffuse the unstirred water layer and would easily access the intestinal apical membrane by an emulsion containing a surfactant with a high HLB (hydrophile lipophile balance)value.
  Japan Society for the Promotion of Science, Grant-in-Aid for Young Scientists (B), Hokkaido University, Principal investigator, Competitive research funding, 24790140
• トランスポータNPC1L1を介したミセル化した基質の細胞内取り込みの可視化法の確立とその輸送メカニズムの解明
  笹川科学研究助成金
  2013 - Feb. 2014
  佐藤夕紀
  公益財団法人 日本科学協会, Principal investigator, Competitive research funding
• 低吸収性成分の吸収改善法の確立と製剤開発への応用
  研究開発助成事業(若手研究人材・ネットワーク育成補助金(Talent補助金)
  2013 - Feb. 2014
  佐藤夕紀
  公益財団法人 北海道科学技術総合振興センター, Principal investigator, Competitive research funding
• 機能性食品成分クルクミンの生体内有用性向上を目的とした吸収改善理論の確立
  2012 - 2013
  佐藤夕紀
  公益財団法人 浦上食品・食文化振興財団, Principal investigator, Competitive research funding
• 難水溶性薬物の乳剤化による経口吸収改善の可否を決定する因子の探索
  調査・研究助成
  2011 - 2012
  菅原満
  公益財団法人一般用医薬品セルフメディケーション振興財団, Competitive research funding
• ルテインの眼への蓄積機構ならびに機能発現との関連性の解明
  研究開発助成事業(タレント補助金)
  2011 - 2012
  佐藤夕紀
  公益財団法人北海道科学技術総合振興センター, Principal investigator, Competitive research funding
• 脂溶性物質の消化管吸収に及ぼす乳化とトランスポータの影響
  研究助成(奨励助成)
  2011 - 2012
  佐藤夕紀
  公益財団法人秋山記念生命科学振興財団, Principal investigator, Competitive research funding

• テアニンの吸収性が改善された組成物
  Patent right, 佐藤夕紀; 武隈洋; 菅原満; 櫻田剛史; 中川公太; 本城政稔, 株式会社ファンケル
  特願2017-011816, 26 Jan. 2017
  特開2018-118928, 02 Aug. 2018
  201803013510580907
• 吸収促進剤およびその利用
  Patent right, 菅原満; 佐藤夕紀; 武隈洋; 丸山真吾
  特願2017-40896, 03 Mar. 2017

• 機能性食品成分の評価法～ルテインを例に～
  2012 - Present
  Lecturer
  公益財団法人 北海道科学技術総合振興センター
  ヘルスイノベーションカレッジ e-learning
• 北海道大学薬学部ＳＰ（模擬患者）会
  2009 - Present
  Informant, Others
• 抗酸化物質はなぜ必要か～食べることとエネルギー代謝～
  2012 - 2015
  Lecturer
  公益財団法人 北海道科学技術総合振興センター
  ヘルスイノベーションカレッジ ベーシックプログラム